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ABSTRACT 
Jaymin Chetan Patel: The Molecular Epidemiology of Malaria in Pregnancy 
(Under the direction of Steven R. Meshnick) 
 
Malaria in pregnancy remains a significant public health problem with an estimated 125 
million pregnant women at risk for Plasmodium falciparum malaria globally every year. 
Pregnancy associated malaria (PAM) causes several adverse pregnancy and birth outcomes 
including maternal anemia, low birth weight (LBW), and small-for-gestational age (SGA). PAM 
also results in 10,000 maternal and 70,000-200,000 infant deaths annually. The key biological 
mechanism by which the plasmodium parasite infects pregnant women is through sequestration 
of infected erythrocytes in the placenta. This sequestration facilitated by a large polymorphic 
plasmodium surface antigen, VAR2CSA. Efforts are underway to develop the first syndrome-
specific malaria vaccine against PAM targeting VAR2CSA. The ID1-DBL2x region of 
VAR2CSA is the minimal binding epitope and has emerged as a lead vaccine candidate. 
However, there is limited data on the extent of genetic diversity of ID1-DBL2x in field isolates. 
Also it is unknown if particular variants are more pathogenic than others.  
In this dissertation, we leveraged advanced molecular methods, population genetics, and 
epidemiology to inform vaccine development efforts. Using samples from P. falciparum-infected 
pregnant women in Malawi and Benin, we characterized the genetic diversity of the ID1-DBL2x 
vaccine target and identified pathogenic clades. We demonstrated that ID1-DBL2x region is 
highly diverse in both countries. We found that the entire 1.6kb region is primarily under 
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balancing selection, confirming its role as an important epitope. Importantly, our phylogenetic 
analyses showed clustering of ID1-DBL2x variants in multiple distinct clades. Two clades 
containing the vaccine referent strains (3D7 and FCR3) were found in both countries in addition 
to three unique clades in Benin. Across multiple birth outcomes we consistently identified 
variants from 3D7-like clade as pathogenic. We did detect LBW and SGA variants in FCR3-like 
clade. However, compared to FCR3-like clade, 3D7-like clade was associated with LBW, SGA, 
and lower infant birth weight. 
Overall, our results provide strong evidence for developing a polyvalent VAR2CSA-
based vaccine against PAM. A vaccine that includes variants from most common and pathogenic 
clades will be more efficacious than current monovalent vaccines in phase I trials. The 
integrative approach used here can be employed to inform development of future malaria vaccine 
candidates targeting polymorphic antigens. 
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CHAPTER ONE: SPECIFIC AIMS 
 
Malaria in pregnancy is a significant public health problem with high disease morbidity 
and mortality. Each year an estimated 125 million pregnant women are at risk of Plasmodium 
falciparum malaria infection [1]. Malaria in pregnancy causes several adverse pregnancy and 
birth outcomes including maternal anemia, severe malaria, spontaneous abortions, stillbirth, 
infant deaths, preterm birth and low birth weight (LBW) and small-for-gestational age (SGA) [2-
12]. In Africa, pregnancy-associated malaria (PAM) is responsible for approximately one million 
cases of infant LBW and of maternal anemia, plus 10,000 maternal and 70,000 to 200,000 infant 
deaths annually [13, 14].  
The adverse consequences of P. falciparum infections on pregnancy are due to the ability 
of infected erythrocytes (IE) to sequester in the placenta. This sequestration of IE in the placenta 
is facilitated by VAR2CSA, a specific variant of Plasmodium falciparum erythrocyte membrane 
protein 1 (PfEMP1).VAR2CSA, a large polymorphic antigen, is expressed on the surface of the 
IE and binds to the placental chondroitin sulfate A (CSA) on the syncytiotrophoblast [15-19]. 
Antibodies against VAR2CSA prevent the cytoadhesion and the adverse effects of PAM [20-23]. 
The N-terminus region of VAR2CSA up to the DBL2x domain is critical to the binding process 
and able to induce an antibody response with similar inhibitory capacity as that elicited against 
full- length VAR2CSA [24-26].  
Recently, the ID1-DBL2x region of VAR2CSA was identified as the minimal binding 
epitope and has emerged as one of the lead vaccine candidates [27-31]. The overall goal of this 
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dissertation is to characterize the genetic diversity of ID1-DBL2x vaccine target region and 
determine its association with adverse birth outcomes in order to identify pathogenic clades and 
inform vaccine development efforts. 
Specifically, we will: 
AIM 1: Characterize the genetic diversity of the 1.6 kb ID1-DBL2x region of var2csa in 
Beninese and Malawian pregnant women at delivery according to gravidity and country. 
Rationale: As efforts are underway to develop an effective vaccine against malaria in pregnancy, 
a recombinant ID1-DBL2x of VAR2CSA is one of the lead vaccine candidates and is currently 
in phase I testing [32, 33]. However, we don’t completely know yet how much diversity is there 
in ID1-DBL2x. Cloning and sequencing of short regions of ID1-DBL2x as well as other regions 
of var2csa have shown significant diversity [28, 29, 34, 35]. The gravidity-dependent nature of 
acquired immunity in pregnant women has shown that multigravid women elicit a stronger 
humoral response to var2csa than primi- and secundigravid women. It is this acquired immunity 
that is hypothesized to protect them and the fetus from the harmful effects of placental malaria 
[2, 3, 10-12, 20, 23, 36, 37]. A more comprehensive understanding on the extent of var2csa 
diversity will aid in vaccine development. 
 
AIM 2: Identify pathogenic clades of ID1-DBL2x by determining the association between 
specific clades and adverse birth outcomes.  
Rationale: We do not know whether specific variants of ID1-DBL2x are more virulent than 
others. Deep sequencing the ID1-DBL2x region of var2csa in a clinically well-defined cohort of 
malaria- infected pregnant women will provide an opportunity to look for pathogenic clades that 
are responsible for the adverse birth outcomes. Due to acquired immunity, different ID1-DBL2x 
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variants will adhere to the CSA with different avidities and parasite will sequester differentially 
in the placenta and this will ultimately affect fetal development [21, 36-38].  
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CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
MALARIA DISEASE BURDEN 
Malaria is a disease caused by infection from the Plasmodium parasite transmitted by the 
female Anopheles mosquito. There are five different species of the Plasmodium parasite that 
infect humans, namely, P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. Of these, 
P. falciparum and P. vivax are the most prevalent and responsible for majority of the global 
malaria disease burden. While P. vivax has a wider geographic distribution because of its ability 
to develop in the Anopheles mosquito vector at lower temperatures and survive at higher 
altitudes, P. falciparum is the deadlier of the two Plasmodium species [39-42]. Following an 
infective bite from the Anopheles mosquito, the incubation period varies from 7 to 30 days 
before development of clinical symptoms. Incubation period also varies by type of infecting 
Plasmodium species with longer periods observed with P. malariae and shorten periods observed 
with P. falciparum infections. Typically, clinical manifestation of malaria infection is 
characterized by paroxysms, which include cyclical fevers, chills, and flu-like illness. The 
spectrum of illness due to malaria infection ranges from asymptomatic infections with no clinical 
symptoms to severe malaria and death. In general, malaria is a completely curable disease. 
However, if misdiagnosed or left untreated, it can lead to severe and complicated manifestations 
of the disease. Severe and complicated malaria typical result in vital organ dysfunction (i.e. 
anemia, jaundice, kidney failure, and coma) and can lead to death [39-41]. 
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Over the last two decades, the world has seen a significant decline in malaria related 
morbidity and mortality. Globally, since 2000, malaria incidence and mortality has declined by 
18% and 48% respectively[42]. Much of the progress made in this time period can be attributed 
to a concerted effort to scale up effective interventions such as indoor residual spraying (IRS), 
insecticide treated bed nets (ITNs), prompt treatment with artemisinin-based combination 
therapy (ACTs), and improvements in diagnosis and case management. Despite the encouraging 
gains, malaria remains a significant public health problem. According the World Health 
Organization (WHO), malaria is endemic in 94 countries with approximately 40% of the world’s 
population (~3.2 billion people) currently at risk. In 2015, the WHO estimated 214 million cases 
(uncertainty range: 149 – 303 million) and 438,000 deaths (uncertainty range: 236,000 – 
635,000) were due to malaria worldwide [39, 42].  
As is the case with many tropical diseases, malaria disproportionately affects the poor 
and under-developed regions of the world [43]. The heaviest burden of disease is experienced by 
individuals in Africa (Figure 2.1). In 2015, 88% of all malaria cases and 90% of all deaths due to 
malaria occurred in Africa alone [39, 42]. Malaria in Africa has not only impacted health of its 
people but also affected economic and social development in that part of the world. The link 
between malaria and poverty is a cyclical one. Poverty promotes conditions where malaria 
transmission is sustained, and in turn malaria hinders economic growth and development, 
propagating the cyclical relationship between the two [44]. Studies have shown that after 
controlling for geographic factors, malaria has a strong negative association with country income 
levels and development indices [45-47]. In 2009, among three countries in sub-Saharan Africa 
(Kenya, Tanzania, and Ghana), total economic costs for treatment and prevention of malaria in 
children under the age of 5 were between $37.8-131.98 million. Additionally, malaria was 
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responsible for $67-290 million in productivity loss due to premature death in these countries 
[48, 49].  
MALARIA IN PREGNANCY 
While malaria infects all people where the parasite is in transmission, specific 
populations are at a higher risk of infection, clinical manifestation of the disease, and death due 
to malaria than others. Vulnerable populations include infants, children under five years of age, 
individuals with HIV/AIDS, migrants, mobile populations, and pregnant women [39, 40]. 
Pregnant women are at a higher risk for malaria infections and its adverse effects than non-
pregnant adults. This increased susceptibility for malaria infection is likely due to their 
suppressed immune system among other factors [2, 3, 10, 11, 39].  
Each year, an estimated 125 million pregnant women are at risk of malaria with 56 
million of those living in high transmission areas [1, 13, 14]. In areas of stable endemic malaria 
transmission in Africa, the prevalence of maternal malaria infection (peripheral or placental 
infection) at delivery is estimated to be around 25% (range: 5-52%) [3].These burden estimates 
are likely underestimated as they are point-prevalence numbers collected at delivery. Prevalence 
estimates at delivery do not account for malaria infections before or after the time of ascertaining 
point-prevalence and would miss infections during pregnancy. Further, these estimates are based 
on microscopy, which fail to diagnose submicroscopic infections that can be detected readily by 
more sensitive methods such as polymerase chain reaction (PCR) and placental histology [3, 8, 
11, 14].  
Malaria in pregnancy (MiP) or pregnancy associated malaria (PAM) is associated with 
several adverse outcomes including maternal anemia, severe malaria, spontaneous abortions, 
stillbirth, infant deaths, preterm birth, low birth weight (LBW), and small-for-gestational age 
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(SGA) [2-14]. Of these, maternal anemia and LBW are the most frequently observed ill effects 
of PAM. In sub-Saharan Africa, malaria is estimated to be responsible for approximately one 
million cases of infant LBW and of maternal anemia, plus 10,000 maternal and 70,000 to 
200,000 infant deaths annually [13, 14]. 
The increased pregnancy-related risk to malaria infection is apparent and higher among 
pregnant women compared to non-pregnant adults despite acquired immunity due to past 
exposure to malaria. The risk of malaria infection during pregnancy is highest during second 
trimester. Little is known about the risk during first trimester; however, susceptibility in first 
trimester must also increase in order to explain the peak prevalence of malaria observed during 
the second trimester [2, 3, 9, 50]. There are several factors that affect the risk of PAM. These 
include age, co-infection with HIV, transmission intensity, use of intermittent preventive 
treatment in pregnancy (IPTp) with sulphadoxine–pyrimethamine (SP), ITNs, and gravidity. Age 
is an important risk factor for malaria in pregnancy. Young pregnant women (especially 
adolescent women) have a higher risk of malaria and its adverse effects than older pregnant 
women. This relationship is observed irrespective of gravidity, implying that age-associated 
immunity influences a woman’s ability to control an infection during pregnancy [3]. Another 
factor that modifies the effect of malaria during pregnancy is co-infection with HIV/AIDS. HIV-
infected pregnant women have shown to have higher prevalence of parasites than HIV-
uninfected pregnant women. Transmission intensity also appears to modify susceptibility to 
malaria infection during pregnancy. In low-transmission areas, women of all gravidities are at 
risk for severe disease and adverse pregnancy outcome. However, that is not the case with 
women in high-transmission areas where parity dependent immunity to ill effects of malaria is 
observed [3, 10, 11, 14].  
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The adverse effects of malaria in pregnancy can be substantially reduced or avoided all 
together using proven interventions such as IPTp- SP and ITNs along with effective case 
management that involves prompt and accurate diagnosis of malaria and anemia [5, 51-53]. 
Currently, the world health organization (WHO) recommends that all women living in stable 
transmission areas such as sub-Saharan Africa receive one dose of IPTp with SP every month 
starting in their second trimester [54]. IPTp and ITNs have shown to be significantly associated 
with reduced odds of delivering a LBW infant (protective efficacy: 21-23%) [5, 55]. One of the 
most important risk factors for PAM is gravidity. The risk of malaria infection and severity of 
disease during pregnancy is modified by gravidity. Particularly, primigravid and secundgravid 
women are at higher risk for adverse effect from malaria infections than multigravid women [2, 
3, 10-12, 20, 23, 36, 37]. This indicates that parity-dependent acquired immunity due to past 
exposures and co-infections with diseases that affect the immune system plays an important role 
in protection against malaria. 
PATHOGENESIS OF MALARIA IN PREGNANCY: ROLE OF VAR2CSA 
 The key mechanism by which malaria infects pregnant women is through the 
accumulation of parasite infected erythrocytes (IE) in the intervillous (vascular) space of the 
placenta [2]. Studies have shown that malaria infection during pregnancy also leads to increased 
frequency of maternal phagocytic cells, especially monocytes in the intervillous space, and 
deposition of hemozoin in phagocytic leukocytes and within fibrin deposits in the intervillous 
space [2, 10, 23, 56, 57]. These changes in the placenta are associated with adverse outcomes 
such as preterm birth, maternal anemia, and decreased birth weight due to fetal growth 
restriction. 
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The sequestration of malaria parasites in the placenta is facilitated by the parasite 
antigens expressed on the surface of the infected erythrocytes that act as ligands to bind to the 
placental chondroitin sulfate A (CSA). The CSA is thought to act as a reversible immobilizer of 
several molecules including hormones and cytokines [10, 58, 59]. The surface antigens involved 
in placental infection are distinct from other surface antigens in their form and function. The 
expression of the surface antigens present in the IE that bind to CSA is responsible for eliciting a 
specific IgG response from the host. The IgG response developed after repeated infections or 
exposures to the malaria parasites mediates the protective immunity that is seen in multigravid 
women. The distinction in form and function of antigens expressed during placental infection 
and the immune response elicited provides an explanation as to why previously clinically 
immune women become susceptible to malaria infection during pregnancy, especially women of 
low gravidities [10, 22, 23, 36].  
The major surface antigenic protein in the parasite that acts as a ligand responsible for the 
cytoadherence of the infected erythrocytes to the CSA belong to a group of proteins called P. 
falciparum Erythrocyte Membrane Protein-1 (PfEMP1). The PfEMP1s are large proteins, 
ranging from 200-350 kDa in size. All PfEMP1s share structural similarities: an N terminal 
segment (NTS); varying numbers of Duffy Binding Like Domains (DBLs); cysteine-rich 
interdomain regions (CIDR or ID); transmembrane domain (TM); C2 domain; and an intra-
cellular acidic terminal segment (ATS). PfEMP1s are expressed during the late erythrocytic 
stage, form a knob like structure on the infected erythrocytes and bind to different adhesins. In 
the case of malaria in pregnancy, the PfEMP1s bind to the CSA [59-61].  
PfEMP1s are coded by a family of a multi-copy gene family named var. There are a total 
of about 60 var genes in the P. falciparum genome [62]. Studies have shown that the expression 
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of the var gene involves a set of regulation mechanisms including activation, switching, and 
silencing of localization sites. Only a single variant of the var gene family is expressed on the 
surface of the infected erythrocyte at any given time. This expression mechanism is mutually 
exclusive meaning that even though there are several var genes, during the course of an 
infection, P. falciparum massively expresses only one var gene at a time and then switches 
expression to another var gene, successively. This switch lets the parasite to undergo clonal 
antigenic variation, allowing the parasite to evade the host immune response and maintain a 
persistent infection. Genetic recombination between var paralogs is thought to be an important 
mechanism in the generation and maintenance of the extreme diversity in the antigen repertoire 
[10, 56, 60, 63-65].  
The var genes are located mostly in the subtelomeric regions and share a similar structure 
[66]. PfEMP1 has a long exon encoding the variable extracellular domain, a conserved intron 
and a short second exon coding for the acid terminal segment [61]. Initially, transcription of two 
variants of the var gene was thought to be critical in the pathogenesis of malaria in pregnancy, 
namely, var1csa and var2csa. Both var1csa and var2csa showed affinity for CSA and 
interclonal conservation. Consequently, a number of studies showed that var1csa is not 
associated with malaria in pregnancy as it is not a target of protective immune response by the 
host (pregnant women) [21]. Further investigation revealed that the other variant, var2csa, was 
indeed present in all P. falciparum clones and was transcribed by CSA-selected and placental 
parasites [15-19]. Several domains of the var2csa gene have shown to have affinity for CSA and 
disruption of var2csa is correlated with inability of infected erythrocytes to bind to the CSA. 
Studies analyzing immune responses to PAM showed that var2csa specific IgG levels in P. 
falciparum exposed adults confirmed the female-restricted and parity dependent nature of 
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var2csa. Importantly, VAR2CSA was present on the surface of intact PAM infected erythrocytes 
but absent from the surface of other non-pregnant adults and children [7, 17, 18, 21, 56, 63].  
High levels of VAR2CSA-specific IgG plasma levels have also been shown to be 
protective against adverse consequences of PAM. In vitro studies using sera from P. falciparum-
exposed multigravid pregnant elicited specific immune responses to two or more domains of 
VAR2CSA. The IgG antibodies targeted the polymorphic rather than the conserved epitopes of 
VAR2CSA indicating that the domains that are accessible to protective antibodies are under 
selection pressure that favor polymorphism. This selection pressure is likely due to the host 
immune response and highlights the significance of VAR2CSA-specific IgG response on PAM 
outcomes [4, 20-22, 37, 38, 67, 68].  
Similar to the other var genes, var2csa comprises of DBL domains and cysteine-rich 
interdomain regions. Specifically, var2csa has the NTS region along with ATS and TM regions 
flanking on the two ends of the gene, and in between it consists of six DBL domains and four 
interdomain regions (Figure 2.2) [16, 19, 21, 24, 63]. Significant effort has been invested to 
identify the regions of var2csa that play a role in the pathogenesis of malaria in pregnancy and 
potential targets for vaccine candidates. Several of the individual domains and interdomain 
regions have shown to bind to the CSA in vitro. DBL2x, DBL3, DBL4, DBL5, and DBL6 along 
with the NTS and interdomain regions 1 (ID1) and 2 (ID2) have shown to elicit immune 
response or be critical in the binding of the infected erythrocytes to the CSA [20, 22, 24, 31, 67-
78].  
However, the N-terminus region of VAR2CSA up to the DBL2x domain has been 
identified as critical to the binding process and able to induce antibody response with similar 
inhibitory capacity as that elicited against full- length VAR2CSA [26, 33]. Recently, studies have 
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shown that a shorter fragment in the N-terminus region, the ID1-DBL2x region plus 93 amino 
acids of the ID2 interdomain was critical to pathogenesis of malaria in pregnancy as it binds to 
the CSA with same avidity as the whole protein. The ID1-DBL2x region is the shortest 
VAR2CSA segment that was able to induce immune response which totally abrogated the 
adhesion of infected erythrocytes with same efficiency and specificity as the full length 
extracellular part of the protein. Further, in context of vaccine development, the ID1-DBL2x 
region also elicited cross-reactive immune response making it a promising vaccine target [27-
31].  
KEY GAPS IN OUR UNDERSTANDING OF VAR2CSA 
 In little over 10 years since var2csa was identified as being essential to the pathogenesis 
of PAM, significant progress has been made to characterize the form and function of this var 
gene. Var2csa has emerged as one of the primary targets for vaccine candidates against PAM 
[10, 23, 33, 79]. However, large gaps in our knowledge of var2csa remain which must be 
addressed before going further with vaccine development. First, even though the var2csa gene is 
more conserved than the other var genes, some studies have indicated that the binding sites 
which are exposed to the immune system are highly polymorphic [16, 21, 30, 58, 65, 78]. 
Knowledge on the extent of genetic diversity of var2csa is very important for vaccine 
development, but remains sparse. Second, given that gravidity modifies the effects of malaria 
infections in pregnancy, very little data is available for specific var2csa variants that are 
responsible for the naturally occurring gravidity-dependent protective immunity [23]. Third, it is 
known that PAM is associated with LBW and anemia among several other adverse outcomes. 
However, no one has identified pathogenic variants or clades of var2csa and the magnitude of its 
association with adverse outcomes. Looking forward, it is likely that any vaccine for pregnant 
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women will be a polyvalent vaccine; hence, it is critical for vaccine development that the most 
pathogenic variants are included in the vaccine to maximize the vaccine’s efficacy and 
effectiveness. Additionally, studies have only looked at either genetic sequences of var2csa or 
analyzed immune responses at the protein level. Very few studies have done both. It is very 
important to identify pathogenic variants of var2csa but it is also essential to determine which of 
the potentially pathogenic variants are actually being transcribed and eliciting an immune 
response from the host. Fourth, the bulk the research so far on var2csa has been in vitro. To truly 
ascertain the pathogenic variants or clades of var2csa that can be potential important vaccine 
candidates, analyzing field isolates from different malaria-endemic areas will provide 
information on the extent of genetic variation and associations to adverse outcomes that 
laboratory isolates and in vitro are unable to.  
RATIONALE 
 PAM is a significant public health problem that has a high disease morbidity and 
mortality. The current preventive measures, IPTp and ITNs are only effective if high levels of 
coverage are achieved and sustained. Recent monitoring and evaluation reports and studies have 
found that the protective effect of IPTp and ITNs for pregnant women in Africa is inadequate 
(24.5-35.3%) [5, 53, 55, 80, 81]. There were several reasons that could explain for the less than 
ideal coverage of IPTp and ITNs, some of which include unclear policies, healthcare 
infrastructure and system issues (i.e. stock outs), confusion over the timing of each dose of SP, 
women’s poor antenatal attendance, and lack of knowledge about preventive measures [5, 51, 54, 
80].  
Additionally, parasite resistance to SP conferred by acquiring multiple mutations in dhps 
and dhfr genes of P. falciparum genome is a major threat to the effectiveness of IPTp. Resistance 
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to SP increases with accumulation of mutations with the highest level of SP resistance observed 
with the dhfr/dhps “quintuple mutant” - dhfr substitutions N51I, C59R, and S108N and the dhps 
substitutions A437G and K540E [82]. The risk of SP failure is higher and rates of parasite 
clearance are lower among pregnant women residing in areas of widespread SP resistance [83]. 
High-resistance areas also experience greater number of reinfections and shorter time to 
reinfections, further providing support of reduced efficacy of SP against malaria infections 
during pregnancy in face of increasing SP resistance. Despite high levels of SP resistance in 
several areas in sub-Saharan Africa, use of IPTp-SP remains associated with improved 
pregnancy and birth outcomes [84, 85]. However, the question is how long will this last before 
IPTp-SP becomes ineffective at preventing adverse outcomes and necessitate alternate strategies. 
Indeed, there are reports that the sextuple mutant - quintuple mutant with an additional 
dhps mutation, A581G exacerbates malaria infections during pregnancy [86]. The sextuple 
mutant, which hasn’t been reported frequently yet, is suggested to confer a significantly greater 
level of SP resistance than the quintuple mutant alone. The sextuple mutant is also linked with 
worsened pregnancy and birth outcomes, including low maternal hemoglobin concentrations at 
birth and birth weight [86, 87]. 
Spread of pyrethroid resistance caused by the kdr mechanism among Anopheles gambiae 
s.s. and Anopheles funestus vectors in sub-Saharan Africa has raised concerns regarding 
effectiveness of ITNs [88, 89]. In areas of moderate pyrethroid resistance, ITNs have remained 
effective [90], but significant loss of insecticidal effect of ITNs has been reported in areas of 
high pyrethroid resistance where kdr resistance levels are ubiquitous [91]. Subpar efficacy of 
ITNs can severely undermine prevention of PAM using bed nets [89]. 
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Given the barriers of preventing PAM, a VAR2CSA-based vaccine would be an effective 
intervention that could achieve and maintain high coverage and supplement existing preventive 
measures easily. The RTS,S/AS01 vaccine designed for the general population showed 
suboptimal efficacy (vaccine efficacy = 25.9% - 36.3%) [92, 93], even after a booster dose. It is 
likely that the effectiveness of the vaccine will be even lower if integrated in routine vaccine 
campaigns and antenatal care. Indeed, the suboptimal efficacy of RTS,S/AS01 can party be 
attributed to plasmodium antigenic diversity [94-97].  
  PAM is curable and preventable, and an effective vaccine for pregnant women at-risk 
living in malaria endemic areas can help substantially reduce the disease burden. Currently, 
phase 1 clinical trials are testing two vaccine candidates (PlacMalVac and PriMalVac) that target 
overlapping constructs in the N-terminus region of VAR2CSA. PlacMalVac targets the ID1-ID2 
region of the FCR3 variant [32] while PriMalVac targets the DBL1x-DBL2x region of the 3D7 
variant (Figure 2.2) [98].  
As ID1-DBL2x region of var2csa is one of the leading vaccine candidate against PAM, 
the gaps in our knowledge highlighted above illustrate the paucity of data and underscored how 
far we are from developing a viable vaccine. Key questions and challenges remain in developing 
an effective vaccine for PAM which include characterization of sequence polymorphism of 
var2csa, identifying the pathogenic variants or clades and determining number of variants that 
should be included in the vaccine for optimal efficacy.  
INNOVATION 
The study is innovative in that it is the one of the first studies that uses long-read next-
generation sequencing technologies to characterize a large functional fragment of the var2csa 
gene (~1600 bp) that has shown to be critical in the pathogenesis of PAM. It is known that the 
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var2csa gene is highly polymorphic and diverse, yet there is very little information on the extent 
of genetic diversity found in field isolates. This study aims to quantify the genetic diversity of 
the ID1-DBL2x region of var2csa in two clinically characterized cohorts of P. falciparum-
infected pregnant women in Benin and Malawi. Deep sequencing of placental malaria parasites 
offer a significant advantage over conventional Sanger sequencing methods as it allows for 
sequencing of mixed and multiple infections, which are prevalent in high malaria transmission 
areas such in sub-Saharan Africa. Additionally, deep sequencing allows for identification and 
quantification of variants occurring at different frequencies, especially low frequencies (<10%) 
[99, 100].  
 Placental blood samples from delivering women will be deep-sequenced using the 
PacBio circular consensus sequencing (CCS) platform. Using PacBio CCS over other commonly 
used deep-sequencing platforms such as Roche-454, Illumina, or Ion Torrent provide the 
advantage of being able to sequencing longer fragments (~5kb vs ~800bp). PacBio would allow 
for sequencing of complete 1.6 kb haplotypes of the ID1-DBL2x region as compared breaking 
up the fragment in shorter pieces and reassembling haplotypes in silico, a method which may 
complicate haplotype reconstruction. 
 There has been no study to date that shows an association between specific var2csa 
variants or clades and pathogenicity in pregnancy and adverse birth outcomes. This is the first 
study that aims to use deep sequencing data in an epidemiological study aimed to identify 
pathogenic variants or clades of var2csa associated with adverse outcomes of malaria in 
pregnancy. The study is unique in that it incorporates state-of-the-art deep-sequencing, 
population genetics and epidemiological methods to comprehensively understand the role 
var2csa plays in the pathogenesis of malaria in pregnancy.   
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Figure 2.1: Global distribution of malaria deaths – 2010. Size of each country is proportional to 
the malaria deaths in the respective country. 
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Figure 2.2: Schematic representation of the var2csa gene. VAR2CSA consists of an N-terminal 
segment (NTS), six Duffy Binding Like Domains (DBL), four cysteine-rich interdomain regions 
(ID), a transmembrane domain (TM), and an intra-cellular acidic terminal segment (ATS). 
Current vaccine development efforts (PlacMalVac and PriMalVac) are targeting the NTS-
DBL2x region. The ID1-DBL2x region has recently been identified as the minimal CSA-binding 
region that contains major protective epitopes and elicits a strong host immune response 
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CHAPTER THREE: DESCRIPTION OF DATA SOURCES 
 
STUDY DESIGN 
The study used existing data and samples collected from two previously completed 
studies in Malawi and Benin. In Malawi, samples were obtained from a randomized controlled 
trial aimed to assess the efficacy of intermittent screening and treatment in pregnancy (ISTp) 
with Sulfadoxine-Pyrimethamine (SP) (Madanitsa et al. 2016). The trial was conducted between 
2010 and 2013 where 1,873 HIV-negative pregnant women were randomized to receive either at 
least three doses of IPTp-SP or at least three screenings with a rapid diagnostic test (RDT) or 
subsequent treatment of RDT-positive cases with Dihydroartemisinin-Piperaquine (DP). In 
Benin, samples were acquired from a prospective cohort study conducted to quantify the effects 
of PAM and investigate immunological responses to malaria infection during pregnancy [50]. 
1,037 pregnant women were enrolled starting in June 2008 and the last delivery occurred in 
September 2010. Follow-up in both studies was done during routine antenatal care visits. 
Women in both studies were enrolled after obtaining signed informed consent. Both 
studies were carefully designed and conducted using expert staff and field workers. Several data 
quality checks were placed in the protocol to ensure minimal errors associated with data 
collection and error. Data from both studies were of good quality and reliable. The current and 
parent studies were approved by institutional review boards at Institut de recherche pour le 
développement in France, Science and Health Faculty (University of Abomey Calavi) in Benin, 
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Liverpool School of Tropical Medicine, Malawian National Health Science Research 
Committee, and University of North Carolina at Chapel Hill. 
Aim 1 of this study used samples collected from pregnant women enrolled in these 
studies in Malawi and Benin at delivery. Specifically, blood samples collected from the placental 
tissue of delivering women were used to sequence and characterize the 1.6 kb fragment of the 
ID1-DBL2x region of var2csa. Aim 2 used genetic sequences generated from Aim 1 as well as 
clinical and demographic data collected from the pregnant women and infants to identify 
pathogenic variants and clades of the ID1-DBL2x region that are associated with adverse birth 
outcomes. 
Given, that the sequestration of plasmodium parasites in the placenta is believed to cause 
the adverse birth outcomes, this study design which uses samples collected at delivery is ideal as 
it gives confirmatory results of the presence of parasites in the placenta at the time of birth. 
Additionally, presence of parasites in the placenta is also an indication of malaria infection in the 
last month of pregnancy, which is a critical period in fetal development.  
An alternative study design would be to use placental as well as multiple peripheral blood 
samples collected throughout the course of pregnancy, specifically early in pregnancy. This 
would enable characterization of var2csa strains in both peripheral and placental infections and 
track the changes in frequencies in the most pathogenic variants over time and between the two 
compartments. However, this alternative study design will be limited in scale given the resources 
and effort required in deep sequencing each sample. The current study design is a critical first 
step in identifying pathogenic variants of var2csa in the placenta and its impact on adverse 
outcomes 
. 
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SOURCE POPULATION AND STUDY AREA  
 The source population included all pregnant women and infants born in the districts of 
Blantyre and Chikwawa in the southern region on Malawi between September 2010 and October 
2013 and in the district of Comé in the Mono province in Benin between June 2008 and 
September 2010. 
Blantyre and Chikwawa are districts located in the southern region of Malawi with a 
population of approximately 950,000. The districts have 2 tertiary hospitals (one in each district) 
where women with high risk pregnancies are referred to for care and delivery. The principal 
malaria vectors in the study area are Anopheles gambiae s.s., and Anopheles funestus. Malaria 
transmission is perennial in these districts with peaks observed during the monsoon season 
(November-March). P. falciparum is the dominant species in circulation as it causes over >90% 
of all malaria infections (Figure 3.1) [101, 102].  
Comé district, with a population of about 58,396 is a semi-rural to rural district located 
about 70 km west from the largest city and economical capital of Benin, Cotonou. The primary 
occupations of inhabitants of the study area are farming, fishing, and trading. Health care is 
provided through three health dispensaries, 11 private clinics, and a district hospital. The area 
experiences two rainy seasons: from April to July and from September to November. The annual 
rainfall is over 1300 mm. Like Malawi, the principal malaria vectors in the study area are 
Anopheles gambiae s.s., and Anopheles funestus. Comé district experiences high malaria 
transmission throughout the year with peak transmission occurring during rainy season. The 
predominant parasite species in circulation in the region is P. falciparum (97%) and the 
entomological inoculation rate ranges from 35 to 60 infective bites per person per year (Figure 
3.2) [103].  
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This identified source population is ideal for the proposed analyses as the burden of 
malaria in pregnancy is highest in sub-Saharan African countries such as Benin and Malawi. 
Further, malaria in pregnancy has been well characterized in the study area through numerous 
studies [50, 85, 104-111]. Both studies from which the data for this project will be acquired have 
prospectively followed pregnant women through delivery and have high quality data. Further, we 
believe the results from this study are generalizable to pregnant women living in other malaria 
endemic sub-Saharan African countries and potentially to countries outside the African sub-
continent. 
STUDY POPULATION 
 The study population included pregnant women who were residing in Blantyre and 
Chikwawa districts between 2010 and 2013 in Malawi and in the Comé district between 2008 
and 2010 in Benin.  
In Malawi, HIV-negative pregnant women were enrolled in the trial starting September 
2010 in the antenatal clinics in Mpemba and Madziabango in Blantyre and Chikwawa districts, 
respectively (Figure 3.1). The inclusion criteria included singleton pregnancy, gestational age of 
16 to 28 weeks, no history of IPTp use during current pregnancy, resident of the study area, and 
willing to deliver at the study clinic or hospital. Women who met the inclusion criteria were 
enrolled in the trial after obtaining informed consent and were randomized to receive either at 
least three doses of IPTp-SP or at least three screenings with an RDT and subsequent treatment 
of RDT-positive cases with DP. Newborn infants to the women enrolled in the trial were 
clinically examined and anthropometric measurements were recorded. Women delivering outside 
the study clinic or hospital were identified by a network of community nurses and traditional 
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birth attendants and birth outcomes along with other relevant information were recorded within 
two days after the delivery (Madanitsa 2016).  
In Benin, women were enrolled starting in June of 2008 in the three dispensaries: Comé, 
Akodeha, and Ouedeme Pedah (Figure 3.2). The inclusion criteria consisted of gestational age 
under 24 weeks, living within 15km from the dispensary for >6 months, and having planned to 
deliver at the hospital. Local midwives performed gynecological examinations and collected 
clinical information on the pregnant women. Pregnant women who met the inclusion criteria 
were then enrolled after study objectives were explained twice and informed consent was 
obtained. Nurses from the community were recruited and trained as project assistants to complete 
questionnaires and collect blood samples from the study participants. In addition to the pregnant 
women, the newborn infants were clinically examined and anthropometric measures were 
collected. For women delivering outside the study time frame, birth outcomes were collected 
from antenatal care book or if the women presented at the study center within two days after 
delivery [50].  
For both aims of this study, we included women testing positive for malaria at delivery in 
their placental blood samples via microscopy or PCR for whom placental blood samples were 
available for ID1-DBL2x genotyping. 
DEMOGRAPHIC AND CLINICAL DATA 
In Malawi, a baseline assessment was conducted at enrollment which included collection 
of demographic and socio-economic information, use of ITNs, IRS, medical and reproductive 
history. Anthropometric measures collected on mothers included height, weight, fundal height, 
last menstrual period, and an ultrasound to determine gestational age. The participants were then 
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randomized to receive the intervention (ISTp-DP) or standard-of-care (IPTp-SP) (Madanitsa et 
al. 2016).  
 During routine antenatal visits, clinical symptoms and illnesses experienced in the last 
month were recorded. The same clinical and biological information as initial visit was collected 
and changes in the demographic data were noted. As part of routine antenatal care in Malawi, 
women received ITNs, iron and folic acid supplements, tetanus vaccination if applicable, 
praziquantel (40 mg/kg single dose) for schistosomiasis, albendazole (400 mg/kg single dose) for 
hookworm, trichuriasis and ascariasis, and albendazole (400 mg/kg per day for 3 days) for 
strongyloidasis (Madanitsa et al. 2016). 
 At delivery, information on the newborn infants included weight, vital signs, and 
congenital anomalies. Gestational age was assessed clinically by using the new Ballard sore. 
After 24 hours, the baby was re-examined for jaundice (Madanitsa et al. 2016). 
In Benin, at the initial visit, for each pregnant woman, information regarding 
reproductive history, current pregnancy, medical history, socio-economic indicators, and use of 
malaria preventive measures such as insecticide treated bed nets was collected. Anthropometric 
measures collected on mothers included axillary temperature, blood pressure, and the mid-upper 
arm circumference (MUAC). Four ultrasound scans were also performed using a portable 
ultrasound system to determine exact term of pregnancy and to evaluate intrauterine growth and 
fetal morphology [50].  
During monthly follow-up antenatal care visits, clinical symptoms and illnesses 
experienced since last follow-up visits were recorded. The same clinical and biological 
information as initial visit was collected and changes in the demographic data were noted. At 
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delivery, measurements of axillary temperature, weight, blood pressure of the mother were 
collected [50]. 
 According to national guidelines, pregnant women were given monthly kits that included 
tablets of iron (200 mg to be taken daily), folic acid (5 mg to be taken daily), and mebendazole 
(500 mg for 3 days) for deworming along with ITNs. Additionally two doses of sulfadoxine 
pyrimethamine (SP) (1500 mg of sulfadoxine and 75 mg of pyrimethamine) were administered 
as IPTp at least one month apart starting in the second trimester of pregnancy [50]. 
 Information collected on the newborn infants included the APGAR score, a method that 
rapidly assess the health of the newborn immediately after birth [112], indications for icterus and 
malformations, anthropological measurements that included weight, height, MUAC, head 
circumference, abdominal circumference, and foot length. Gestational age was assessed 
clinically by using the new Ballard score [113].   
OUTCOME ASSESSMENT 
It is known that PAM is associated with poor infant health and survival. It is believed that 
PAM affects infant’s health through preterm delivery and low birth weight through fetal growth 
restriction among other pathways. The outcomes of interest in this study were adverse birth 
outcomes. Birth weight was the primary outcome of interest in this study. Birth weight was 
measured by an electronic scale at the time of the infant’s birth in both studies in Benin and 
Malawi. If a birth occurred outside the study frame, birth outcomes were assessed from antenatal 
cards including birth weight in Benin or within 48 hours of birth in person in Malawi. Birth 
weight was recorded as a continuous variable in grams. Gestational age was determined by four 
ultrasound measurements during the course of the pregnancy in Benin and one ultrasound in 
Malawi.  
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Birth weight was included in the study as a categorical as well as a continuous outcome. 
Low birth weight (LBW) was defined according to the WHO’s criteria as infant with a birth 
weight of less than 2500 grams [114]. Additionally, to account for confounding in birth weight 
due to gestational age [115-119], small-for-gestational age (SGA) was calculated for each infant 
using nomograms from previous studies from the study areas. SGA, which takes into account 
gestational age as well as birth weight give a more accurate representation of fetal growth in the 
study population [120, 121]. SGA was defined as infant with a birth weight below the 10th 
percentile for babies of the same gestational age at delivery 
EXPOSURE ASSESSMENT 
The main exposure of interest for this study was the genetic sequence of the ID1-DBL2x 
region of var2csa. The ID1-DBL2x region was characterized by targeted deep-sequencing using 
the PacBio consensus deep-sequencing (CCS) platform. Sequences from PacBio were clustered 
to using a k-mer clustering algorithm to generate a list of unique ID1-DBL2x variants and their 
relative frequencies infecting the pregnant women in our study population. Phased consensus 
genetic sequences from each woman were used in the analyses of both aims. Additionally, results 
of the phylogenetic clustering performed in aim 1 were used to help inform epidemiologic 
modeling approaches in aim 2.  
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Figure 3.1: Malawi Study Site 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Benin Study Site 
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CHAPTER FOUR: METHODS 
 
DNA EXTRACTION 
 Among samples from the ISTp trial in Malawi, genomic DNA was extracted from dried 
blood spots (DBS) using 20% Chelex-100 (Bio-Rad, Richmond, CA) [122]. DBS were hole-
punched into 96-well plates and incubated overnight at 4 °C in 1ml of 1x PBS and 50 uL of 10% 
saponin. After a wash with 1x PBS, 50 µl of 20% Chelex was added to each sample and 
incubated at 95°C for 12 minutes. Genomic DNA in the solution was aspirated to separate it 
from the Chelex beads and stored at -20°C for downstream molecular testing and PCR 
amplifications.  
 For Benin, genomic DNA was extracted from RBC pellets using Thermo Scientific 
GeneJET DNA extraction kit (Catalog #K0781) as recommended by the manufacturer. Briefly, 
packed RBCs were digested with Proteinase K and incubated with ethanol at 56°C for ten 
minutes. DNA was separated from the lysate via purification column, and eluted in water, and 
stored at -20°C. 
ID1-DBL2X PCR ASSAY 
 We developed a hemi-nested PCR amplification strategy to amplify the 1.6 kb ID1-
DBL2x region of var2csa from genomic DNA. First all publicly-available genetic sequences of 
var2csa from GenBank and PlasmoDB were downloaded and aligned in MEGA 6.0 [123]. 
Published primers targeting the 1.6 kb region [28] were superimposed on the alignment to ensure 
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that the primers were indeed in the conserved region. An outer reverse primer was designed for 
the first round of the hemi-nested PCR (Table 4.1). Barcodes were attached to the forward and 
reverse primers for the second round PCR (Appendix A). The second round of hemi-nested PCR 
was a designed to be a touchdown PCR in order to increase the specificity of the DNA 
amplification. 
 The PCR reaction mix for the first round contained: 2.5µl of Roche Hi-Fi buffer, 0.5 µl 
of 10 mM dNTPs, 20 µM of each primer, 1.2 µl of 25 mM MgCl2, 0.25 µl of Roche Hi-Fi DNA 
polymerase, 1.25 µl of DMSO, and 5 µl of DNA template in a 25 µl reaction. The first round 
PCR cycling conditions were as follows: 95°C for 2m, 35 cycles of 95°C for 30s, 52°C for 30s, 
and 72°C for 3min, and a final extension of 72°C for 7m. PCR products from the primary round 
were then used as DNA template for the second round PCR. The PCR reaction mix for the 
second round contained: 2.5µl of Roche Hi-Fi buffer, 0.5 µl of 10 mM dNTPs, 20 µM of each 
barcoded primer, 0.25 µl of Roche Hi-Fi DNA polymerase, 1.25 µl of DMSO, and 2 µl of 
primary PCR product in a 25 µl reaction. The second round PCR cycling conditions were as 
follows: 95°C for 2m, 15 cycles of 95°C for 30s, 67-52°C for 30s (-1°C per cycle during first 15 
cycles, then 52°C for 25 cycles), and 72°C for 3m, and a final extension of 72°C for 7m. All 
second round PCR products were visualized on a 1% agarose gel. 
PACBIO CIRCULAR CONSENSUS SEQUENCING (CCS) 
 Genomic DNA from each clinical sample was amplified in technical duplicate PCR 
reactions using unique forward and reverse barcoded primers for each replicate. Concentrations 
of successful amplifications were quantified using the Genomic DNA ScreenTape assay on the 
Agilent 2200 TapeStation system. PCR products were then pooled together for deep sequencing 
on PacBio CCS platform using the P5-C4 chemistry. PCR products with unique barcodes were 
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mixed in an equimolar fashion for each PacBio Single Molecule, Real-Time (SMRT) sequencing 
cell. This was done to ensure all PCR products would be sequenced with equal probability. Each 
PacBio SMRT cell was gel extracted and purified using Qiagen gel extraction kit as per 
manufacturer’s protocol. The SMRT cells were quantified again to ensure adequate 
concentration and quantity of DNA was present before sequencing. 
CLUSTERING OF NEXT-GENERATION SEQUENCING DATA 
Raw sequences from PacBio were cleaned and clustered using a novel clustering 
algorithm based on k-mer distances [124]. First, sequences sharing the same barcodes were 
clustered using the k-mer clustering algorithm. For each sequence, all its k-mers were indexed 
and k-mer distances were created by counting the k-mers shared between two sequences and 
dividing by the maximum number of k-mers the two sequences could share. The range of values 
for k-mer distance is between 0 and 1 with 0 being no k-mers shared and 1 being all k-mers 
shared. K-mer distances were calculated at several k-mer lengths and the rate at which the k-mer 
distance decreased with increasing length was compared to monoclonal PacBio samples rates to 
cluster similar sequences. Second, after within-PCR replicate (same barcode) clustering, 
between-PCR replicate (same samples) or population clustering was performed to determine the 
similarity between technical replicates from each sample, identify different variants of the ID1-
DBL2x region, and estimate the frequencies of each variant. Identification of variants and 
estimation of their frequencies was within each sample as well as between samples at a 
population level. The end result of k-mer clustering yielded one or more phased consensus 
sequences for each woman present in the study population (Figure 4.1). 
 
 
31 
VALIDATION STUDY 
As the PCR assay and bioinformatics clustering of a long fragment of var2csa has not 
been previously reported, we conducted a validation study using pools of reference genomic 
parasite lines to ensure that our assay and clustering algorithm was appropriate and accurate. We 
mixed seven reference parasite lines (3D7, FCR3, 7G8, DD2, K1, RO33, and V1/S) in varying 
frequencies (1-50%) in five pools and deep-sequenced it on the PacBio CCS platform. The 
sequences derived from deep-sequencing were then clustered using the k-mer clustering 
algorithm. We estimated the component parasite lines for each pool and their relative frequency. 
We then compared the results of de novo clustering to the expected and reference- guided 
observed frequencies.  
SPECIFIC AIM 1 
STUDY SAMPLE 
The study sample for Specific Aim 1 included pregnant women enrolled in the parent 
studies in Benin and Malawi whose placental samples collected at delivery were amplified and 
deep-sequenced successfully and for whom we had clinical and demographic data. To 
characterize the genetic diversity of the ID1-DBL2x region, we calculated measures of alpha 
(within-group) and beta (between-group) diversity. We then compared these measures between 
the two countries and between women of differing gravidities. 
CHARACTERIZING ALPHA (α) DIVERSITY 
 To estimate the alpha diversity, we calculated rarefaction curves, expected heterozygosity 
(He), Shannon index (H’), abundance coverage estimator (ACE), incidence coverage estimator 
(ICE), Chao richness estimators, and maximum composite likelihood (MLE) phylogenetic trees. 
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To estimate species richness of the ID1-DBL2x region of var2csa, we calculated 
rarefaction curves [125] in Malawi and Benin as well as by gravidity. As observed species 
richness is highly sensitive to sample size and diversity of the marker being used, a simple ratio 
of species per sampling unit may distort richness values. Hence rarefaction curves were 
calculated taking into account how sampling was conducted. Rarefaction curves of haplotypes 
were calculated in EstimateS [126] as: 
𝑆𝑠𝑎𝑚𝑝𝑙𝑒(𝑡) = 𝑆𝑜𝑏𝑠 −  ∑ [
(
𝑇 − 𝑌𝑖
𝑡
)
(𝑇
𝑡
)
]
𝑌𝑖 >0
  
where, Ssample (t) is expected number of species, Sobs is the actual number of species observed, T 
is the total number of sampling units, t is the incident sample, and Yi is the observed species 
incidence frequencies. Rarefaction curves were bootstrapped 1000 times with replacement to 
generate 95% confidence intervals. Since var2csa is highly diverse and we were likely to find 
many more variants of var2csa through next-generation sequencing, we extrapolated the 
rarefaction curves by 100 additional samples to predict how species richness would change if our 
sample size was larger.  
Expected heterozygosity (He) was calculated at each locus within each country and 
within women of differing gravidities as [127]: 
𝐻𝑒 = [
𝑛
𝑛 − 1
] [1 − ∑ 𝑝𝑖
2]
𝑛
𝑖=1
 
where n is the number of isolates sampled and 𝑝𝑖 is the frequency of the ith allele. All calculated 
estimates of He were then bootstrapped 1000 times to estimate the precision of the estimates and 
test if He was statistically different between the two countries and different by gravidity. 
Additionally, to examine how genetic diversity in the variants affected protein sequences, we 
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calculated He at each amino acid position among variants in Malawi and Benin from translated 
protein sequences. 
 Shannon index (H’) was calculated for the ID1-DBL2x populations within each country 
and within women of differing gravidities as [128]: 
𝐻 ′ =  − ∑ 𝑝𝑖  𝑙𝑛 𝑝𝑖
𝑅
𝑖=1
 
where pi is the proportion of individuals found in the ith species. All estimates of H’ were 
bootstrapped 1000 times with replacement to generate precision estimates. 
 Abundance coverage estimator (ACE) was calculated for the ID1-DBL2x populations 
within each country and within women of differing gravidities as [129]: 
𝑆𝑎𝑐𝑒 =  𝑆𝑎𝑏𝑢𝑛𝑑 + 
𝑆𝑟𝑎𝑟𝑒
𝐶𝑎𝑐𝑒
+
𝐹1
𝐶𝑎𝑐𝑒
 𝛾𝑎𝑐𝑒
2   
 where Sabund is the number of abundant species when all samples are pooled, Srare is the number 
of rare species (each with 10 or fewer individuals) when all samples are pooled, Cace is the 
sample abundance coverage estimator, F1 is the frequency of singletons, and 𝛾𝑎𝑐𝑒
2  is the estimated 
coefficient of variation of singletons. All estimates of ACE were bootstrapped 1000 times with 
replacement to generate precision estimates.  
 Incidence coverage estimator (ICE) was calculated for the ID1-DBL2x populations 
within each country and within women of differing gravidities as [129]: 
𝑆𝑖𝑐𝑒 =  𝑆𝑓𝑟𝑒𝑞 +  
𝑆inf𝑟  
𝐶𝑖𝑐𝑒
+
𝑄1
𝐶𝑖𝑐𝑒
 𝛾𝑖𝑐𝑒
2  
where Sfreq if the number of frequent species (found in >10 samples), Sinfr is the number of 
infrequent species (found in <10 samples), Cice is sample incidence coverage estimator,Q1 is the 
frequencies of unique species, and 𝛾𝑖𝑐𝑒
2 is the estimated coefficient of variation of unique species. 
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All estimates of ICE were bootstrapped 1000 times with replacement to generate precision 
estimates. 
 The Chao estimates were calculated for the ID1-DBL2x populations within each country 
and within women of differing gravidities as [130]: 
𝑆𝐶ℎ𝑎𝑜1 =  𝑆𝑜𝑏𝑠 +  (
𝑛 − 1
𝑛
)
𝐹1 (𝐹1 − 1)
2(𝐹2 + 1)
 
 
where Sobs is the total number of species observed in all samples pooled, n is the number of 
samples, F1 is the frequency of singletons, and F2 is the frequency of doubletons. 
𝑆𝐶ℎ𝑎𝑜2 =  𝑆𝑜𝑏𝑠 + (
𝑚 − 1
𝑚
) (
𝑄1(𝑄1 − 1)
2(𝑄2 + 1)
) 
where Sobs is the total number of species observed in all samples pooled, m is the number of 
samples, Q1 is the frequencies of unique species, and Q2 is the frequencies of duplicate species. 
Statistically significant differences in alpha diversity metrics between different groups were 
tested using Kruskal–Wallis test. An α of 0.05 was determined a priori to test for significant 
differences. 
Using genetic sequences from the haplotypes, we constructed phylogenetic trees using 
the maximum composite likelihood method in MEGA6. Genetic distances in the maximum 
composite likelihood method were calculated using the Tamura-Nei model [131]: 
𝑑 = −𝑏𝑙𝑜𝑔𝑒(1 − 𝑝 𝑏⁄ ) 
where p is the proportion of sites with different nucleotides and 
𝑏 =  
1
2
[1 − ∑ 𝑔𝑖
2 + 𝑝2/𝑐
4
𝑖=1
] 
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𝑐 =  ∑ ∑
𝑥𝑖𝑗
2
2𝑔𝑖𝑔𝑗
4
𝑗=𝑖+1
3
𝑖=1
 
where xij is the relative frequency of the nucleotide pair i and j, gis are the nucleotide frequencies. 
The maximum composite likelihood phylogenetic trees were bootstrapped 1000 times to 
compute branch support and provide precision in the differences observed in the trees. Bootstrap 
values of greater than 80% were used as cutoff point to identify significant differentiation 
between variants and clusters. All phylogenetic trees were visualized using the APE package for 
R [132].  
CHARACTERIZING BETA (β) DIVERSITY 
To characterize genetic relatedness among the ID1-DBL2x variant populations between 
Malawi and Benin as well as between the different clades, we calculated Wright’s fixation index 
(FST) [133] as. 
𝐹𝑆𝑇 =  
𝜋𝐵𝑒𝑡𝑤𝑒𝑒𝑛 −  𝜋𝑊𝑖𝑡ℎ𝑖𝑛
𝜋𝐵𝑒𝑡𝑤𝑒𝑒𝑛
 
where πBetween is the average number of pairwise nucleotide differences between two variants 
from two different sub-populations and πWithin is the average number of pairwise nucleotide 
differences between two variants from the same sub-population. The FST index quantifies genetic 
relatedness based on allele frequencies among population and ranges from 0 to 1, where 0 
signifies a genetically identical population and 1 signifies completely differentiated populations. 
The FST analyses were performed using a sliding window to identify regions along the vaccine 
target that would account for the genetic relatedness between countries and clades.  
We performed a principal coordinate analysis (PCoA) to assess the genetic relatedness 
between population of variants from different countries, gravidities, and clades identified by 
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phylogenetic clustering. FST values were used as the genetic distance matrix for the PCoA. The 
top coordinates explaining the most amount of variation were used to visualize the genetic 
relatedness between the clades. 
 We calculated nucleotide diversity (π) and Tajima’s D test [134] on the entire ID1-
DBL2x region as well as with a sliding window approach to assess the selection pressures acting 
upon vaccine target[135]. Tajima’s D was calculated on ID1-DBL2x variant populations by 
country and major clades as follows: 
𝐷 =  
?̂? −  𝜃?̂?
√𝑉𝑎𝑟(?̂? −  𝜃?̂? )
 
where π is the average number of pairwise differences and ϴw is the Watterson’s estimator of ϴ 
calculated as: 
𝜃?̂? =  
𝑆𝑛
𝑎𝑛
 
where Sn is the number segregating sites in a population and an is: 
𝑎𝑛 =  ∑
1
𝑖
𝑛−1
𝑖=1
 
 All measures of genetic relatedness and selection (FST, PCoA, π, Tajima’s D) were calculated in 
R using the adegenet [49] and popgenome [56] packages.  
 
 
 
 
 
37 
SPECIFIC AIM 2  
STUDY SAMPLE 
The study sample for Specific Aim 2 included pregnant women enrolled in the parent 
studies in Benin and Malawi whose placental samples collected at delivery were amplified and 
deep-sequenced successfully and for whom we had clinical and demographic data. 
PHYLOGENETIC AND STATISTICAL ANALYSES  
 We examined associations between clades and birth outcomes to identify pathogenic 
clades. Outcomes of interest were birth weight, low birth weight (LBW), and small- for-
gestational age (SGA). At delivery, infant birth weight was recorded to the nearest gram within 
24 hours using a calibrated digital scale. LBW was defined according to World Health 
Organization’s criteria as infant with a birth weight of less than 2500 grams [114]. SGA was 
defined as infant with a birth weight below the 10th percentile for babies of the same gestational 
age at delivery [120, 121, 136]. 
 Unique variants identified in our study population were analyzed phylogenetically to 
detect clustering. We constructed phylogenetic trees using the maximum composite likelihood 
(MLE) method in MEGA6 [123]. Genetic distances in the maximum composite likelihood 
method were calculated using the Tamura-Nei model [131]. The MLE phylogenetic trees were 
then bootstrapped 1000 times to compute branch support and provide precision in the clustering 
detected in the trees. All phylogenetic trees were visualized using the APE package for R [132]. 
Bootstrap values of greater than 80% were used as cutoff point to identify significant 
differentiation between variants and clusters. 
 Associations between specific clades and birth outcomes were first explored by 
examining the clustering of adverse birth outcomes (i.e. LBW and SGA) in the MLE 
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phylogenetic trees in Malawi or Benin, respectively. Pregnant women were categorized based on 
the respective clade in which the variants detected from their samples clustered. We then used 
linear and logistic regression to estimate the effect of clades on birth weight, LBW, and SGA, 
respectively. We controlled for potential confounders and standardized the groups defined by 
clades to the marginal distribution of potential confounders in the study population using inverse 
probability weights. The denominator of the weights for the different clades of ID1-DBL2x was 
estimated using polytomous logistic regression, conditional on parity. For the pooled analyses, 
we also included country in estimating the denominator of the weights. Weights were stabilized 
using the marginal distribution of the ID1-DBL2x clades in our study population. We estimated 
differences in birth weight and relative odds of LBW and SGA associated with infection with 
each clade, using FCR3 as the referent category. All analyses were conducted using SAS version 
9.3 (SAS Institute, Cary, North Carolina). 
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Table 4.1: ID1-DBL2x hemi-nested PCR primer sequences  
Primer Name 5'→3' 
ID1-F* GATCCTTATTCCGCAGAATA 
CIDR-R_Heminested TTTCTTTGTTCCACTGTTCAAA 
CIDR-R* GTCGTGTATGTTGTCCA 
*Bordbar et. al, 2014 
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Figure 4.1: Schematic representation of the bioinformatics clustering pipeline employed in this 
study. Pools of amplified ID1-DBL2x from individual women in technical replicates using 
barcoded primers were sequenced on PacBio CCS platform. Reads were clustering using a k-mer 
algorithm to identify unique ID1-DBL2x variants in the study population. 
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CHAPTER FIVE: RESULTS. GENETIC DIVERSITY AND POPULATION 
STRUCTURE OF VAR2CSA ID1-DBL2X IN MALAWI AND BENIN: IMPLICATIONS 
FOR VACCINE DEVELOPMENT 
 
STUDY POPULATION 
 P. falciparum was detected by PCR in the placental blood samples of 281(18.8%) women 
in Malawi and 175(27.6%) women in Benin.; of these, 281 (100%) and 126 (72%) samples were 
available from Malawi and Benin, respectively. Of the samples available, we were able to 
successfully amplify the 1.6kb ID1-DBL2x region of var2csa in a total of 101 samples – 56 
(19.9%) from Malawi and 45 (37.5%) from Benin, constituting the analytic population. The 
mean maternal age of the 101 women was 22.5 years (standard deviation (SD) ±5.5 years) and 
the mean gestational age at delivery was 38.1 weeks (SD ± 2 weeks). Of the women included in 
our analyses 38.6% (n = 39) were primigravid, 28.7% (n = 29) were secundigravid, and 32.7% (n 
= 33) were multigravid (Table 5.1). Among the available P. falciparum positive specimens, there 
were no significant differences between women whose samples amplified successfully and those 
whose samples did not with respect to demographic characteristics (Table 5.2). Samples from 
Benin amplified more readily than those from Malawi; this variability was likely due to 
differences in sample storage (DBS versus RBCs) across study sites.  
VALIDATION OF GENOTYPING APPROACH 
We conducted a validation study to determine if our laboratory and bioinformatics 
approach was sensitive and precise at genotyping ID1-DBL2x. To do so, pools of seven genomic 
parasite lines in varying frequencies were amplified, sequenced, and clustered via our PCR assay 
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and k-mer clustering pipeline. In five distinct multiclonal template mixtures, we were 
able to accurately detect each of the seven parasite genomic lines. Additionally, we detected 
parasite haplotypes that were included in as little as 5% of the mixed template (Figure 5.1). 
Quantitatively the observed frequencies of each parasite line correlated well with the expected 
frequencies (R2=0.82) (Figure 5.2). The results from k-mer clustering showed reliable variant 
calling and clustering of ID1-DBL2x variants. The clustering of variants using the k-mer 
algorithm produced similar results as the reference-guided clustering (Figure 5.1 and Figure 5.2).  
ID1-DBL2X DEEP-SEQUENCING AMONG CLINICAL ISOLATES 
For our clinical samples, a total 523,482 CCS reads were obtained from 14 PacBio 
SMRT cells. After extracting reads by barcoded primer sequences and filtering based on size and 
quality requirements, 256,377 (48.98%) reads were used for k-mer clustering to identify unique 
variants in our study population (Figure 5.3). The median sequence length from the extracted 
reads was 1594bp (range: 1400 – 1700bp). The median coverage from CCS was 1795 reads per 
sample (range: 16 – 9241).  
Overall, we identified 152 unique ID1-DBL2x variants, 95 in Malawi and 57 in Benin. 
Of these 152 variants, 17 were observed in more than one woman. Interestingly, one variant was 
shared between Malawi and Benin (Table 5.1). The mean multiplicity of infection (MOI) was 
1.88 (range: 1-7) in Malawi and 1.56 (range: 1-4) in Benin (Table 5.1). Overall the ID1-DBL2x 
fragment showed significant genetic variation with ~30% (n = 470) of the region containing 
polymorphic sites (Table 5.3).  
WITHIN-GROUP (ALPHA) DIVERSITY OF ID1-DBL2X 
The within-group (alpha) diversity of ID1-DBL2x at the two study sites was assessed by 
rarefaction, which compensates for the difference in depth of sampling (Figure 5.4). The two 
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curves overlap for most of the sampled region but only the extrapolated curve for Malawi 
approaches its asymptote (Figure 5.4). This suggests that ID1-DBL2x is more diverse in Benin as 
compared to Malawi. This finding is corroborated by other alpha diversity metrics (Table 5.4). 
The metrics which do not compensate for sampling (He and H’) showed no difference between 
the sites while the metrics that do (ACE, ICE, and Chao), as predicted, demonstrate significantly 
greater diversity in Benin. He at the amino acid level along the ID1-DBL2x fragment showed 
regions of high diversity separated by conserved regions. Amino acid diversity was also notably 
higher in Benin, especially in the ID1 region (Figure 5.5).  
PHYLOGENETIC CLUSTERING 
We then compared all variants in Malawi and Benin phylogenetically to identify any 
clustering of ID1-DBL2x in our study population. The maximum-likelihood phylogenetic trees 
clustered the variants in Malawi in two significantly distinct clades (bootstrap values >80%). The 
two clades co-clustered with the two referent strains which were used to design the current 
vaccine candidates (3D7 and FCR3) (Figure 5.6). In contrast, the phylogenetic trees in Benin 
clustered the variants into five significantly distinct clades (bootstrap values >80%). In addition 
to the 3D7-like and FCR3-like clades identified in Malawi, three clades unique to Benin were 
detected (Figure 5.6).  
The principal coordinate analysis (PCoA) showed that the vast majority of the difference 
in the populations was explained by clade, rather than by gravidity or country. The first two 
principal coordinates (PC1 & PC2) accounted for 21% of the variation. As expected, the PC1-
PC2 plot showed a significant differentiation between the 3D7 and FCR3 clade. Interestingly, 
while clades 4 and 5 appear to be closely related to 3D7, variants in clade 3 displayed a genetic 
background resembling both 3D7 and FCR3 clades, indicating a possible recombination event 
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(Figure 5.7). The PC1-PC3 plot (Figure 5.7) showed similar genetic relatedness between clades 
as was observed in the PC1-PC2 plot. 
BETWEEN-GROUP (BETA) DIVERSITY OF ID1-DBL2X 
To study the genetic relatedness between ID1-DBL2x populations in our study, we 
calculated Wright’s Fixation index (FST) with a sliding window over the entire 1.6kb region for 
pairwise comparison between countries, women with differing gravidities, and the two vaccine 
clades (3D7 and FCR3). The FST values comparing variants from women with differing 
gravidities approached zero (range: 0-0.11), indicating high degree of genetic similarity (data not 
shown). The FST values between Malawi and Benin were again close to zero indicating that the 
ID1-DBL2x populations in the two countries did not differ significantly as we detected variants 
from the two major clades in both countries. However, when comparing FST values between 3D7 
and FCR3 clade, overall the two populations look similar except for a ~100bp region where the 
two populations differ significantly (FST = 0.26-1.0) (Figure 5.8).  
DETECTING SIGNATURES OF SELECTION WITHIN ID1-DBL2X 
Detecting signatures of selection on the vaccine target was done through calculating 
Tajima’s D across the entire ID1-DBL2x region. The Tajima’s D test statistic can indicate 
whether a nucleotide sequence is under directional selection (D<0), genetic drift (D=0), or 
balancing selection (D>0). Among all groups (i.e. country and gravidity), the ID1-DBL2x 
variants in our study population demonstrated significant signatures of balancing selection 
(range: 1.183 – 1.976) (Table 5.3). To determine whether the entire region was uniformly under 
balancing selection, we applied Tajima’s D test using a sliding window approach. Scanning 
across the 1.6kb fragment, we observed regions under high balancing selection along with 
regions of directional selection (Figure 5.9). The dimorphic region between the 3D7 and FCR3 
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clades displayed the strongest signal for balancing selection indicating that the region interacts 
with human immune system and may play an important role in vaccine efficacy.  
DISCUSSION 
The ID1-DBL2x region of VAR2CSA is an important PAM vaccine candidate, as it is the 
minimal CSA-binding region that elicits an immune response. Phase 1 clinical trials are testing 
two vaccines (PlacMalVac and PriMalVac) that target overlapping constructs of distinct variants 
of this region [32, 98]. PlacMalVac targets the ID1-ID2 region of the FCR3 variant while 
PriMalVac targets the DBL1x-DBL2x region of the 3D7 variant (Figure 2.2). Our study on the 
genetic diversity of ID1-DBL2x can directly inform these ongoing vaccine development efforts.  
The results from our study demonstrate that ID1-DBL2x is indeed highly diverse in 
Malawi and Benin. The population genetic analyses indicate high species richness and within 
group diversity of the ID1-DBL2x population in both countries and among women with differing 
gravidities. Furthermore, signatures of selection indicate that the region is primarily under 
balancing selection. Most importantly, we also report significant clustering of variants into 
distinct clades that will likely warrant a polyvalent vaccine and an approach that can take the 
relevant genetic diversity into account.  
 To our knowledge this is the first study to employ long-read next-generation sequencing 
of the 1.6kb 1D1-DBL2x region from clinical isolates to characterize the genetic diversity of this 
vaccine target. Previous studies have relied on Sanger sequencing or cloning, both of which limit 
depth and sensitivity, or on breaking up the fragment into smaller fragment to deep-sequence and 
reassembling haplotypes in silico, a method which may complicate haplotype reconstruction [16, 
17, 24, 28, 38, 78, 137]. The PacBio CCS platform allowed us to sequence a long fragment of 
var2csa at great depth without requiring assembly of haplotypes. Additionally, barcoding 
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individual samples allowed us to link variants detected through deep-sequencing to individual 
women and their clinical and demographic data. Due to the high rates of polymorphism, polyA 
repeats, and PacBio error rate, variant calling through conventional software was not adequate. 
As a result, we implemented a k-mer clustering algorithm which provided a more appropriate 
way to determine unique variants of var2csa.  
Our population genetic analyses revealed high species richness of the sequenced 
fragment of var2csa in both Malawi and Benin. This is in concordance with previously reported 
overall species richness of var genes [138]. Using FST as a measure of genetic relatedness, we 
observed that overall, the ID1-DBL2x populations in Malawi and Benin were very similar and 
the genetic differences observed were not explained by geography. Likewise, the ID1-DBL2x 
variant populations were similar between primi-, secundi-, and multigravid women. This 
suggests that VAR2CSA-based vaccines targeting the ID1-DBL2x region can be effective across 
geographic and demographic subpopulations.  
We found that the ID1-DBL2x variants clustered in distinct phylogenetic clades. Two of 
the clades which contained the vaccine referent strains, 3D7-like and FCR3-like variants, were 
found in both countries. In addition to those two clades, we detected three other clades in Benin 
that were not present in Malawi. A similar clustering has been reported previously [139]. 
Variants from one of the clades unique to Benin (clade 3) displayed genetic similarities to both 
3D7 and FCR3 clades in the PCoA analyses. This suggests that the variants in clade 3 are a 
product of potential recombination as they contained a 3D7 as well as a FCR3 genetic backbone. 
The variants from the two major (3D7 and FCR3) clades were largely similar to each other 
across the 1.6kb region except for a ~100bp region that was very different between the two 
clades. This dimorphic region reported before in West Africa is important as this difference 
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likely explains the suboptimal cross-protective effect (between 3D7 and FCR3 clades) observed 
among the current vaccine candidates [31, 137].  
The ID1-DBL2x region is under balancing selection as indicated by overall positive 
Tajima D’s values. Thus corroborates its role as an important epitope. Scanning across the 1.6kb 
region, we detected signatures of both balancing as well as directional selection. While the ID1-
DBL2x populations in Malawi and Benin displayed similar signatures of selection, the variants 
in 3D7 and FCR3 clades displayed contrasting signatures of selection in the ID1 region. 
Additionally, the dimorphic region between the 3D7 and FCR3 clades is under strong balancing 
selection, suggesting that it is a target of host immunity. Taking the relevant genetic diversity 
into account when designing a vaccine will be critical in producing a candidate that has excellent 
cross-protective effect. Efforts need to continue further characterization of the genetic diversity 
of var2csa vaccine targets among clinical isolates and identify pathogenic variants and clades 
that are associated with adverse pregnancy and birth outcomes. Including these pathogenic 
variants and clades in a polyvalent vaccine can help maximize the vaccine’s efficacy and 
effectiveness.  
We were limited in the number of samples we were able to include in our study. This was 
due to the difficulty in amplifying a long fragment of a hypervariable gene from DNA extracted 
from dried blood spots in Malawi. The generalizability of our results is also limited as we had 
access to samples from only two countries in Africa. However, the results from our study agree 
with other studies that were able to deep-sequence smaller fragment of var2csa from multiple 
countries in Africa as well as from Asia and South America [28].  
We employed an integrative approach, using molecular epidemiology, next-generation 
sequencing, and population genetics to examine the antigenic diversity of var2csa, identify 
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immunologically relevant selection pressures and signatures of genetic relatedness to inform 
vaccine development efforts. Previous attempts to develop a general vaccine against malaria 
have not taken antigenic diversity into account; this is one possible explanation for suboptimal 
efficacy and effectiveness [92, 95]. The results from our study provide further support for the 
development of polyvalent vaccines against malaria. As clinical trials get underway for testing 
vaccines against PAM, characterizing genetic diversity and monitoring parasite populations will 
help explain changes that affect vaccine efficacy and inform future vaccine improvement and 
development efforts.  
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Table 5.1: Description of the study population 
 
Group  
Samples, n (%) 101 (100) 
     Benin 45 (44.6) 
          Akodeha 19 (18.8) 
          Comé 12 (11.9) 
          Ouedeme Pedah 14 (13.9) 
    
     Malawi 56 (55.4) 
          Mpemba 24 (23.8) 
          Madziabango 21 (20.8) 
          Chikwawa 11 (10.9) 
    
Maternal Age   
     Mean (SD) 22.5 (5.5) 
    
Gestational Age   
     Mean (SD) 38.1(2) 
    
Gravidity, n (%)   
     Primigravid 39(38.6) 
     Secundigravid 29(28.7) 
     Multigravid 33(32.7) 
    
MOI, mean (range)  
     Benin 1.56 (1-4) 
     Malawi 1.88 (1-7) 
    
Unique var2csa variants, n (%) 152 
     Benin 57 (37.7) 
     Malawi 95 (62.9) 
    
Variants shared between samples 17 
Variants shared between countries 1 
Variants shared between sites  11 
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Table 5.2: Characteristics of PCR amplified and unamplified samples 
 
  Group Amplified 
(n=101) 
Not Amplified 
(n = 315) 
P values 
Maternal Age    
     Mean (SD) 22.5 (5.5) 24.5 (6.2) 0.82 
     
Gestational Age   0.83 
     Mean (SD) 38.1(2) 38.87(1.9)  
     
Gravidity, n (%)    
     Primigravid 39(38.6) 97 (30.8) 0.15 
   Secundigravid 29(28.7) 89 (28.3) 0.99 
     Multigravid 31(32.7) 129 (41.0) 0.16 
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Table 5.3: Nucleotide diversity (π) and Tajima’s D 
Group n* π** Segregating 
sites 
Tajima's 
D 
All 152 0.105 470 1.781 
Malawi 57 0.096 415 1.976 
Benin 95 0.113 460 1.699 
      
Primigravid 63 0.099 459 1.183 
Secundigravid 49 0.11 451 1.244 
Multigravid 53 0.115 458 1.467 
*number of haplotypes 
**nucleotide diversity 
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Table 5.4: Within-group (alpha) diversity of ID1-DBL2x populations 
   *number of haplotypes 
  
Group n* 
H
E
 
(SD) 
Shannon 
(SD) 
ACE 
(SD) 
ICE 
(SD) 
Chao1 
(SD) 
Chao2 
(SD) 
All 152 
0.266 
(0.027) 
4.5 
(0.08) 
157.12 
(21.96) 
157.36 
(22.08) 
149.51 
(16.65) 
149.31 
(16.59) 
Malawi 95 
0.307 
(0.019) 
4.04 
(0.13) 
104.19 
(19.32) 
104.51 
(19.5) 
100.21 
(15.31) 
99.91 
(15.19) 
Benin 57 
0.298 
(0.037) 
3.98 
(0.02) 
257.3 
(23.87) 
259.7 
(24.09) 
201.81 
(64.7) 
200.8 
(64.16) 
        
Primigravid 63 
0.274 
(0.027) 
3.56 
(0.09) 
65.06 
(16.13) 
65.29 
(16.33) 
61.84 
(12.2) 
61.61 
(12.09) 
Secundigravid 49 
0.299 
(0.032) 
3.34 
(0.13) 
55.97 
(18.49) 
56.29 
(18.8) 
52.72 
(12.82 
52.42 
(12.65) 
Multigravid 53 
0.300 
(0.035) 
3.41 
(0.12) 
57.91 
(15.59) 
57.71 
(15.85) 
57.25 
(13.65) 
56.94 
(13.47) 
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Figure 5.1: Results from the validation study - expected and observed frequencies of the seven 
genomic parasite lines in five pools using referent-based and k-mer clustering.  
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Figure 5.2: Scatterplot of expected and observed frequencies of ID1-ID2x haplotypes in mixtures 
of reference parasite lines. 
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Figure 5.3: Flow chart of the processing and filtering raw reads by barcodes and quality.  
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Figure 5.4: Rarefaction curves of ID1-DBL2x variants in Malawi (blue) and Benin (red). 
Calculated rarefaction curves are represented by solid lines. Extrapolated curves are depicted by 
dotted lines. The rarefaction curves were bootstrapped 1000 times to generate the 95% 
confidence intervals (CIs), which are represented by lightly shaded red and blue. 
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Figure 5.5: Expected heterozygosity (He) at each amino acid position along the ID1-DBL2x 
region among variants populations in Malawi (blue) and Benin (red). 
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Figure 5.6: Maximum-likelihood phylogenetic trees of ID1-DBL2x variants in (A) Malawi and (B) Benin. All trees were bootstrapped 
1000x and bootstrap values >80 were used as cutoff points for significant branch differentiation. In Malawi, variants clustered in two 
distinct clades with the two referent strains (3D7 and FCR3). In Benin, in addition to the 3D7 and FCR3 clades, three other clades 
were detected. 
A        B 
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Figure 5.7: Principal Coordinate Analysis (PCoA) of ID1-DBL2x variants in the study population. (A) PCoA plot using principal 
coordinates 1 and 2 (PC1 & PC2) (B) PCoA plot using principal coordinates 1 and 3 (PC1 & PC3). Each dot represents the unique 
ID1-DBL2x variants colored according to the clade. The axes indicate which coordinates are being plotted and the percentage of 
variation explained by that particular axis. 
 
A           B 
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Figure 5.8: FST values using a sliding window approach (window size = 10bp, step size = 10bp) 
across the 1.6kb ID1-DBL2x region of var2csa. FST values were calculated between the two 
major vaccine clades (3D7 and FCR3). FST values range from 0 to 1, where 0 signifies a 
genetically identical population and 1 signifies completely differentiated populations. Sliding 
window FST analyses show that scanning across the region, the parasite populations in the two 
clades are very similar except for a ~100 bp region (highlighted in gray) where the two 
populations differ substantially.  
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Figure 5.9: Tajima’s D using a sliding window approach (window size = 100bp, step size = 
25bp) across the 1.6kb ID1-DBL2x region of var2csa. (A) Tajima’s D calculated for ID1-
DBL2x populations in Malawi and Benin and (B) 3D7 and FCR3 clades (dimorphic region 
highlighted in gray). Tajima D values less than 0 indicate directional selection, equal to 0 
indicate genetic drift, and greater than 0 indicate balancing selection.  
 
 
A)  
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CHAPTER SIX: RESULTS. IDENTIFICATION OF PATHOGENIC VAR2CSA 
CLADES: ASSOCATIONS BETWEEN ID1-DBL2X CLADES AND BIRTH OUTCOMES 
 
STUDY POPULATION 
A total of 281 (18.8%) women in Malawi and 175 (27.6%) women in Benin tested 
positive for P. falciparum malaria by PCR in placental blood samples at delivery. Of the women 
that tested positive, samples from 281 (100%) and 126 (72%) women were available from 
Malawi and Benin, respectively. We were able to amplify 101 (24.8%) of the available samples – 
56 (19.9%) from Malawi and 45 (37.5%) in Benin, constituting our analytic population. Women 
included in our analytic population were similar to the overall cohort with respect to 
demographic characteristics (Table 5.2). The variability in amplification rate was likely due to 
differences in sample storage across study sites as samples extracted from DBS (Malawi) 
amplified less readily than samples stored as RBC (Benin). Between countries, there were 
significant differences in maternal age (mean (standard deviation [SD]) 20.5 years (4.6) in 
Malawi versus 24 years (6.3) in Benin; p value = 0.013) and gestational age at delivery (mean 
(SD) 37.1 (3.4) weeks in Malawi versus 39.2 weeks (39.2) in Benin; p value <0.001). There were 
also a significantly higher proportion of primiparous women in Malawi than Benin (51.8% 
versus 22.2%; p value = 0.004) (Table 6.1).  
In our analytic population, the mean (SD) infant birthweight in both countries was similar 
(Malawi – 2677.7grams [539.6g] versus 2840g [379.7g]; p value = 0.146). The prevalence of 
LBW was 19.6% (n=11) in Malawi and 13.3% (n=6) in Benin and prevalence of SGA was 
 64 
16.1% (n=9) in Malawi and 24.4% (n=11) in Benin. There were no significant 
differences in the adverse birth outcomes, LBW or SGA by country (Table 6.1).  
ID1-DBL2X DISTRIBUTION – PHYLOGENETIC ANALYSES 
From the 101 pregnant women included in our study, we identified 152 unique ID1-
DBL2x variants – 95 in Malawi and 57 in Benin. Of the 152 unique variants, 17 variants were 
found in multiple women, and one variant was shared between Malawi and Benin. The mean 
multiplicity of infection (MOI) was 1.88 (range: 1-7) in Malawi and 1.56 (range: 1-4) in Benin. 
The phylogenetic analysis revealed significant clustering of ID1-DBL2x variants in our study 
population. The MLE phylogenetic trees in Malawi clustered the variants in two significantly 
distinct clades (bootstrap values >80%), which also contained the two referent strains which 
were used to design the current vaccine candidates (3D7 and FCR3) (Figure 6.1 and Figure 6.2). 
In Malawi, 21 (37.5%) and 22 (39.3%) women were infected with only 3D7-like and FCR3-like 
variants, respectively. Variants from both clades were detected in 13 (23.2%) women (Table 
6.2). 
In Benin, the MLE phylogenetic trees identified five distinct clades (bootstrap values 
>80%). In addition to the 3D7-like and FCR3-like clades identified in Malawi, three clades 
unique to Benin were detected (Figure 6.1and Figure 6.2). While 4 (8.9%) and 13 (28.9%) 
women were infected with only 3D7-like and FCR3-like variants, respectively; 17 women 
(37.8%) were infected with a variant from one of the three clades unique to Benin. We also 
observed 6 (13.3%) women infected with both 3D7-like and FCR3-like variants, 4 (8.9%) 
women infected with FCR3-like variants and variants from the three Benin unique clades, and 
one (2.2%) woman who was infected with variants from the two vaccine clades as well as the 
other clades (Table 6.2).  
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ASSOCIATION BETWEEN ID1-DBL2X CLADES AND BIRTH OUTCOMES 
BIRTHWEIGHT 
 In unadjusted descriptive analyses, the median (IQR) infant birthweight among mothers 
in Malawi infected with only 3D7-like variants was 2450g (2150g – 2850g) whereas mothers 
infected with only FCR3-like variants had a median birthweight of 2800g (2600g – 2960g). In 
Benin, the median (IQR) infant birthweight of mothers infected with only 3D7-like variants was 
2710g (2490g – 2825g) and 2720g (2580g – 3250g) for those women infected with only FCR3-
like variants (Table 6.2).  
In the adjusted analyses, after accounting for parity and country through IPW, women 
infected with only 3D7-like variants observed a lower infant birthweight (-267.99g; 95% CI: -
466.43g – -69.55g) (Table 3). This reduction in infant birthweight was present when stratified by 
country, but attenuated substantially in Benin, potentially in part due to lower prevalence of 3D7-
like variants in this population. In Malawi, the infant birthweight was reduced by 330.97g (95% 
CI: -628.44g – -33.49) and in Benin, infant birthweight was reduced by 147.88g (95% CI: -
530.06 – 234.g) after adjusting for parity (Table 6.3).  
 In Benin, women infected with variants from clades other than the vaccine clades were 
found to have somewhat increased infant birthweight (185.63g; 95% CI: -67.80– 439.06g) as 
compared to women infected with only FCR3-like variants. Similarly, women infected with both 
3D7-like and FCR3-like variants reported an increase in infant birthweight across all populations 
(Table 6.3). However, women infected with variants from both vaccine and non-vaccine clades 
reported lower infant birthweight across both countries (range: -280g – -133.41g) (Table 6.3).  
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SMALL-FOR-GESTATIONAL AGE (SGA) AND LOW BIRTHWEIGHT (LBW) 
Given the sparse distribution of categorical adverse birth outcomes, SGA and LBW in 
our study population (Table 6.2), we modeled the effect of only the vaccine clades (3D7-like and 
FCR3-like) on SGA and LBW. The unadjusted prevalence of LBW was higher in women with 
only 3D7-like variants than women with only FCR3-like variants in Malawi (47.6% versus 
4.6%) and in Benin (25% versus 15.4%) (Table 6.2). Phylogenetically, while there were a few 
LBW variants clustered in the FCR3-like clade, the majority of the LBW variants in Malawi 
were present in the 3D7-like clade (Figure 6.1). In Benin, the distribution of LBW variants was 
more evenly distributed between 3D7-like and FCR3-like clade (Figure 6.1). In pooled analysis, 
women infected with only 3D7-like variants had higher odds of LBW than women infected with 
only FCR3-like variants (OR: 8.19; 95% CI: 1.65 – 40.57), after adjusting for parity and country. 
Unadjusted prevalence of SGA was higher among women infected with only 3D7-like 
variants than women infected with only FCR3-like variants in Malawi (28.1% versus 9.1%) and 
in Benin (50% versus 23.1%) (Table 6.2). Variants present in women delivering SGA infants 
clustered more readily in 3D7-like clade in Malawi (Figure 6.2) whereas in Benin, the 
distribution again was more even between 3D7-like and FCR3-like clades (Figure 6.2). We also 
identified four SGA variants clustered in clade 3 (Figure 6.2). As observed with LBW, in pooled 
analysis, compared to women infected with only FCR3-like variants, women infected with only 
3D7-like variants had higher odds of delivering a SGA infant (OR 2.45; 95% CI 0.67 – 8.94). 
After adjusting for parity and country, being infected with only 3D7-like variants was still 
associated with higher odds of delivering a SGA infant (OR 3.65; 95% CI 1.00 – 13.38) (Table 
6.4). When stratifying by country, women infected with only 3D7-like variants consistently had 
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higher odds of delivering a SGA infant in Malawi (OR: 5.21; 95% CI: 0.77 – 35.41) and in 
Benin (OR: 2.98; 95% CI: 0.27 – 32.48) (Table 6.4.)  
DISCUSSION 
A VAR2CSA-based vaccine against PAM will be the first syndrome-specific malaria 
vaccine and may substantially reduce one the major causes of adverse pregnancy and birth 
outcomes in tropical countries, especially in sub-Saharan Africa. Current vaccine candidates 
(PlacMalVac and PriMalVac) against PAM are targeting overlapping constructs of the N-
terminal region of VAR2CSA. PlacMalVac targets the ID1-ID2 region of the FCR3 variant 
while PriMalVac targets the DBL1x-DBL2x region of the 3D7 variant (Figure 2.2) [32, 98]. 
Both vaccine candidates, now in Phase 1 testing in West Africa, are monovalent vaccines 
designed using two different referent strains. Given that VAR2CSA is highly polymorphic, any 
effective VAR2CSA-based vaccine aimed at reducing the burden of PAM will have to be 
polyvalent. Additionally, it is important to identify and include variants that are associated with 
adverse pregnancy and birth outcomes. Hence, it is critical for vaccine development to take 
relevant genetic diversity into account to maximize vaccine efficacy. We have previously 
characterized genetic diversity of ID1-DBL2x from clinical isolates and demonstrated that the 
ID1-DBL2x region is indeed highly diverse in sub-Saharan Africa. In this study, we identified 
pathogenic clades of ID1-DBL2x that are associated with adverse birth outcomes among P. 
falciparum infected pregnant women in Malawi and Benin.  
The ID1-DBL2x variants in our study population clustered in multiple phylogenetic 
clades. In Malawi, the variants clustered in two distinct clades, while variants in Benin clustered 
in five distinct clades. In both countries, we detected clades which contained the vaccine referent 
strains (3D7 and FCR3) as well as other clades only unique to Benin, however, the 3D7 clade 
 68 
was much less prevalent in Benin overall, found in only 22% of Benin participants in comparison 
to 61% of Malawi participants. The LBW and SGA variants clustered more readily in 3D7-like 
clade in Malawi but were evenly distributed between 3D7-like and FCR3-like clades in Benin. 
Across multiple birth outcomes, we detected a trend that consistently identified 3D7-like clade as 
pathogenic in comparison to FCR3-like clade. Compared with variants from FCR3-like clade, 
variants from 3D7-like clade were associated with lower infant birth weight, LBW, and SGA in 
our study population. Women infected with variants only from 3D7-like clade saw reductions in 
infant birth weight ranging from 147.7g to 331.0g as compared to variants from only FCR3-like 
clade in both Malawi and Benin respectively (Table 6.3). This reduction in birth weight is 
clinically significant and comparable to the reduction in birth weight observed due to active 
maternal smoking – approximately a 200 gram deficit [140]. Women infected with variants from 
only 3D7-like clade also had higher odds of delivering a LBW and SGA infant. This persistent 
trend along with the detection of 3D7-like clade in multiple countries supports including variants 
from 3D7-like clade in a polyvalent VAR2CSA-based vaccine.  
Even though we used FCR3-like clade as a referent group to estimate relative 
pathogenicity, we observed that LBW and SGA variants indeed clustered in FCR3-like clade in 
both Malawi and Benin. Albeit small numbers of LBW and SGA, of interest was the observation 
that variants from the FCR3-like clade appear to be more pathogenic in Benin than Malawi. 
While only 4.6% of the variants in FCR3-like clade in Malawi had LBW, 15.4% of the variants 
in Benin had LBW. Similarly, only 9.1% of the variants in FCR3-like clade in Malawi had SGA 
compared to 23.1% in Benin. These site-specific differences of the effect of FCR3-like clade on 
adverse birth outcomes again emphasize the need to develop a polyvalent vaccine which contains 
variants from the most common clades that are associated with adverse birth outcomes.  
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This is the first study investigating effects of specific genetic variants of var2csa on 
clinical outcomes. Employing long-read next-generation sequencing of ID1-DBL2x region of 
var2csa in a clinically defined cohort of malaria- infected pregnant women provided an excellent 
opportunity to look for pathogenic clades of var2csa most responsible for adverse birth 
outcomes. This study complements previous efforts to characterize the role of ID1-DBL2x 
region of var2csa in PAM pathogenesis and associations between immunological responses to 
placental malaria and adverse birth outcomes. Additionally, using clinical isolates from multiple 
malaria-endemic countries with differing transmission intensities allowed us to better 
characterize the extent of ID1-DBL2x genetic diversity and associations with adverse outcomes 
that were not possible from in vitro studies using laboratory isolates [20, 21, 29, 31]. 
Our study has its limitations. We were limited by the number of P. falciparum infected 
placental samples we were able to include in our analyses. This was in part due to low yield in 
amplifying ID1-DBL2x, a long hypervariable region of var2csa from DNA extracted from dried 
blood spots in Malawi. We also had sparse distribution of our categorical adverse birth outcomes 
that precluded us from detecting significant associations. However, including birth weight as a 
continuous outcome and controlling for confounders using inverse probability weights increased 
our ability estimate effect of vaccine clades on infant birth weight. Given that gestational age at 
delivery is a strong predictor of infant birth weight and is itself affected by malaria exposure 
during pregnancy, gestational age at delivery may be a mediator on the causal pathway of ID1-
DBL2x clade and birth weight. We were therefore, limited in our ability to estimate the direct 
effect of ID1-DBL2x clade on birth weight. We were able to only estimate the total effect of 
ID1-DBL2x clade on birth weight, including the effect of gestational age on birth weight. This 
limited our ability to draw inferences on the effect of ID1-DBL2x clades on fetal growth 
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specifically. Nonetheless, our study approach integrating next-generation sequencing with 
population genetics and epidemiological modeling provided high resolution data on placental 
plasmodium parasites and identify trends of pathogenicity.  
  Recently, RTS,S a general vaccine for malaria completed phase III testing and was 
recommended by WHO for pilot implementation in 3-5 sub-Saharan African countries [141]. 
However, it is still not an ideal vaccine as efficacy was suboptimal (25.9-36.3%) [92] and 
effectiveness will likely be lower. The suboptimal efficacy could partially be explained by 
parasite antigen diversity that was not taken into account by the vaccine [95, 96]. Therefore, 
learning from past vaccine efforts, relevant genetic diversity must be taken into account in the 
early stages of development of a VAR2CSA-vaccine against PAM. The results from our study 
further provide support for a polyvalent VAR2CSA-based vaccine against PAM as adverse birth 
outcomes were detected in multiple clades including two clades which contained the referent 
strains used to design the current vaccine candidates. An effective VAR2CSA vaccine will add 
to the arsenal of IPTp and ITN to fight against PAM. 
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Table 6.1: Study population characteristics 
 
  Malawi (n=56)   Benin (n=45) p value 
Maternal Age (mean, (SD)) 20.5 (4.6)   24.0 (6.3) 0.013 
Gestational Age (mean, (SD)) 37.1 (3.4)   39.2 (1.6) <0.001 
Parity (n, (%))         
     Primiparous 29 (51.8)   10 (22.2) 0.004 
     Multiparous 27 (48.2)   35 (77.8)   
Birthweight (mean, (SD)) 2677.7 (539.6)   2840 (379.7) 0.146 
Low birthweight (LBW), n(%) 11 (19.6)   6 (13.3) 0.459 
Small-for-Gestational-Age (SGA), n(%) 9 (16.1)   11 (24.4) 0.535 
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Table 6.2: Distribution of infant birth weight and adverse birth outcomes by ID1-DBL2x clades 
in Malawi and Benin 
 
 
Malawi (n=56) 
 
Benin (n=45) 
Clades N 
SGA 
(%) 
LBW 
(%) 
Birthweight 
(median (IQR))   N 
SGA 
(%) 
LBW 
(%) 
Birthweight 
(median (IQR)) 
3D7 21 
6 
(28.1) 
10 
(47.6) 
2450  
(2150 - 2850)   4 
2 
(50.0) 
1 
(25.0) 
2710  
(2490 - 2825) 
FCR3 22 
2  
(9.1) 
1  
(4.6) 
2800  
(2600 - 2960)   13 
3 
(23.1) 
2 
(15.4) 
2720  
(2580 - 3250) 
3D7+FCR3 13 
1  
(7.7)   
2850  
(2700 - 3000)   6 
2 
(33.3) 
1 
(16.7) 
2900  
(2550 - 3200) 
Other*           17 
3 
(17.6) 1 (5.9) 
3100  
(2790 - 3160) 
FCR3+ 
Other*           4   
1 
(25.0) 
2550  
(2365 - 2610) 
3D7+ 
FCR3+Other*           1 
1 
(100)   2700 
*Other clade includes variants from clades 3, 4, and 5 
 
  
 73 
Table 6.3: Associations between ID1-DBL2x clades and infant birthweight (grams) 
 
*Adjusted for country (pooled analysis only) and parity using inverse probability weights (IPW) 
**Change in infant birth weight (grams) 
† Other clade includes variants from clades 3, 4, and 5  
Birthweight  Crude   Adjusted* 
  Effect** 95% CI   Effect** 95% CI 
Pooled               
FCR3 REF - -  REF - - 
3D7 -251.49 -474.28 -28.69   -267.99 -466.43 -69.55 
3D7+FCR3 99.55 -151.45 350.56   22.36 -199.23 243.94 
                
Malawi               
FCR3 REF - -  REF - - 
3D7 -262.24 -557.46 33.00   -330.97 -628.44 -33.49 
3D7+FCR3 151.76 -204.90 508.43   100.75 -260.62 462.12 
                
Benin               
FCR3 REF - -  REF - - 
3D7 -153.41 -548.08 241.26   -147.66 -530.06 234.75 
3D7+FCR3 14.10 -328.97 357.15   21.99 -310.39 354.39 
Other† 187.33 -74.23 448.89   185.63 -67.80 439.06 
FCR3 + other†  -323.41 -718.08 71.26   -280.21 -662.62 102.19 
3D7+FCR3+other† -110.91 -816.91 595.09   -133.24 -906.49 640.02 
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Table 6.4: Associations between ID1-DBL2x vaccine clades (3D7 & FCR3) and small- for-
gestational age (SGA) 
 
 
 
 
 
 
*Reference group = FCR3 clade 
** Adjusted for country (pooled analysis only) and parity using inverse probability weights (IPW) 
 
  
  Crude   Adjusted** 
  OR* 95% CI   OR* 95% CI 
Pooled 2.45 0.67 8.94   3.65 1.00 13.38 
             
     Malawi 3.46 0.59 20.20   5.21 0.77 35.41 
        
     Benin 2.67 0.25 28.44   2.98 0.27 32.48 
  
 
7
5 
Figure 6.1: Maximum-likelihood phylogenetic trees of ID1-DBL2x variants in (A) Malawi and (B) Benin by low birth weight (LBW). 
All trees were bootstrapped 1000x and bootstrap values >80 were used as cutoff points for significant branch differentiation. LBW 
was defined according to World Health Organization’s criteria as infant with a birth weight of less than 2500 grams. 3D7 (green) and 
FCR3 (purple) were detected in both countries. Majority of the LBW variants (red) in Malawi were present in the 3D7-like clade 
whereas in Benin, the LBW variants were more evenly distributed between 3D7-like and FCR3-like clades. 
A           B 
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Figure 6.2: Maximum-likelihood phylogenetic trees of ID1-DBL2x variants in (A) Malawi and (B) Benin by small- for-gestational age 
(SGA). All trees were bootstrapped 1000x and bootstrap values >80 were used as cutoff points for significant branch differentiation. 
SGA was defined as infant with a birth weight below the 10th percentile for babies of the same gestational age at delivery. 3D7 
(green) and FCR3 (purple) were detected in both countries. SGA variants (red) clustered more readily in 3D7-like clade in Malawi 
whereas in Benin, the distribution was more even between 3D7-like and FCR3-like clades. We also identified four SGA variants 
clustered in clade 3. 
A          B 
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CHAPTER SEVEN: DISCUSSION 
 
Pregnancy-associated malaria (PAM) is an important preventable cause of several 
pregnancy and birth outcomes including maternal and infant death, especially in sub-Saharan 
Africa [3, 5, 11-14, 117]. The role of VAR2CSA is critical in PAM pathogenesis and immune 
response [15-21]. VAR2CSA is a large polymorphic protein coded by one of the var genes, 
which are known to be highly diverse [34, 65, 78, 138]. While still in its infancy, efforts are 
underway to develop the first syndrome-specific malaria vaccine that can be administered to 
women of child-bearing age to reduce PAM-associated morbidity and mortality. Currently, two 
VAR2CSA-based vaccine candidates (PlacMalVac and PrimMalVac) targeting overlapping 
constructs of the N-terminal region are in phase I trials in Benin and Burkina Faso [32, 98].  
 Developing vaccines against malaria in the past have achieved limited success as only 
one candidate so far has completed phase III testing. The RTS,S/AS01 vaccine, recently 
approved by the European Medicines Agency (EMA) and supported by the WHO for pilot 
testing has shown suboptimal protective efficacy (vaccine efficacy = 25.9% - 36.3%) [92]. Why 
even after more than three decades of research and testing did RTS,S/AS01 provide only 
moderate protection? Part of the suboptimal efficacy can be explained by lack of parasite antigen 
diversity accounted for during the vaccine development stage. Like all other vaccines against P. 
falciparum malaria, RTS,S/AS01 too was designed using genetic sequences from a single, well-
characterized reference strain – 3D7 [96]. As a result, strain-specific immunity was the culprit 
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and RTS,S/AS01 vaccine efficacy was higher against clinical malaria with infections with 3D7 
strains than against clinical malaria from non-vaccine strains [95].  
So what can we learn from past malaria vaccine efforts to help us develop an effective 
vaccine against PAM? The current VAR2CSA-based vaccine candidates are also designed using 
genetic sequences from a single reference parasite line - 3D7 or FCR3 [33]. Given the high 
diversity of the plasmodium parasite, the question remains whether the current approach for 
aVAR2CSA-based vaccine is adequate or do we need to fully assess the extent of genetic 
diversity of the parasite antigen to prevent vaccine escape due to strain-specific efficacy. The 
genetic diversity of the VAR2CSA-based vaccine candidates is not yet well characterized among 
clinical isolates. How diverse is the N-terminal region of var2csa and are there patterns of 
genetic clustering that we can leverage in designing a vaccine? Additionally, including specific 
variants from clades of var2csa that are most responsible for the adverse pregnancy and birth 
outcomes will boost vaccine efficacy and reduce PAM related morbidity and mortality, however, 
no pathogenic clades have been identified yet. Hence, the driving motivations of this dissertation 
were to characterize the extent of genetic diversity of the ID-DBL2x region of var2csa, one of 
the two VAR2CSA-based vaccine candidates and identify pathogenic variants or clades to 
directly inform vaccine development efforts.  
SUMMARY OF FINDINGS 
 The studies completed as part of this dissertation report several findings that may help 
VAR2CSA-based vaccine development against PAM. The integrative study approach taken here 
provides a proof-of-concept to investigate other vaccine candidates and inform future malaria 
vaccine development efforts. In our first aim, we used long-read next-generation sequencing of 
clinical isolates collected from P. falciparum-infected pregnant women in Malawi and Benin to 
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characterize the genetic diversity of the 1.6kb fragment of ID1-DBL2x region of var2csa. We 
demonstrated that ID1-DBL2x is highly diverse in both Malawi and Benin as we detected 
immense species richness and within group diversity in both countries among women with 
differing gravidities. We found that the entire 1.6 kb region is primarily under balancing 
selection, confirming the role of ID1-DBL2x as an important epitope. Most importantly, our 
phylogenetic analyses showed that the ID1-DBL2x variants clustered significantly into multiple 
distinct clades in Malawi and Benin. We detected clades that contained the vaccine reference 
strains (3D7 and FCR3) in both Malawi and Benin. In addition to the vaccine clades, we found 
three clades unique to Benin. We also reported a ~100bp dimorphic region in the DBL2x domain 
which was present in both countries and has been reported previously in West Africa. Overall, 
the results from aim 1 provide strong evidence that will likely warrant a polyvalent vaccine that 
includes variants from multiple clades.  
 In our second aim, we identified pathogenic clades of ID1-DBL2x in our study 
population by estimating the effect of specific ID1-DLB2x clades on adverse birth outcomes. 
Across multiple birth outcomes (birth weight, LBW, and SGA), we detected a trend that 
identified variants from the 3D7-like clade as relatively pathogenic. Phylogenetically, the LBW 
and SGA variants clustered more readily in the 3D7-like clade in Malawi but were more evenly 
distributed in Benin among the two vaccine clades. In our study population, compared to variants 
from the FCR3-like clade, variants from 3D7-like clade were associated with LBW, SGA, and 
lower infant birth weight.  
Even though we used FCR3-like clade as a reference to estimate relative pathogenicity, 
we did detect LBW and SGA variants clustering in FCR3-like clade. We also observed some 
site-specific differences of the effect of FCR3-like clade as variants from the FCR3-like clade in 
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Benin had higher prevalence of LBW and SGA than variants from the FCR3-like clade in 
Malawi. The results from aim 2 helped identify potential variants and clades that are most 
responsible for adverse birth outcomes and should be included in a VAR2CSA-based vaccine.  
Overall, results from both aims taken together provide strong support for developing a 
polyvalent vaccine which includes variants from multiple genetically distinct clades as well as 
variants from clades associated with adverse birth outcomes to maximize the vaccine’s efficacy.  
CONCLUSIONS  
 The current preventive interventions, IPTp-SP and ITNs are only effective at high 
coverage levels and there has been a consistent low uptake of these interventions over the past 
few decades [5, 51, 53, 55, 80, 81]. Spread of pyrethroid resistance caused by the kdr mechanism 
among Anopheles vectors in sub-Saharan Africa has raised concerns regarding effectiveness of 
ITNs [88, 89]. In areas of moderate pyrethroid resistance, ITNs have remained effective [90], but 
significant loss of insecticidal effect of ITNs has been reported in areas of high pyrethroid 
resistance where kdr resistance levels are ubiquitous [91]. Subpar efficacy of ITNs can severely 
undermine prevention of PAM using bed nets.  
Parasite resistance to SP conferred by acquiring successive multiple mutations in Pfdhps 
and Pfdhfr genes also threaten the effectiveness of IPTp-SP [53, 82]. The risk of SP failure is 
higher and rates of parasite clearance are lower among pregnant women living in malaria-
endemic areas where SP resistance is widespread [84]. Despite high levels of SP resistance in 
several areas in sub-Saharan Africa, use of IPTp-SP remains associated with improved 
pregnancy and birth outcomes [84, 85]. However, the question is how long will this last before 
IPTp-SP becomes ineffective at preventing adverse outcomes and necessitate implantation of 
alternate strategies.  
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To that end, an effective vaccine against PAM can help substantially reduce one the 
major causes of adverse pregnancy and birth outcomes in tropical countries, especially in sub-
Saharan Africa. The overall goal of this dissertation was to directly inform efforts to develop a 
VAR2CSA-based vaccine against PAM. We showed that the current monovalent vaccine 
candidates designed using two different reference strains will likely not confer complete 
protection against PAM-related adverse outcomes, specifically the vaccine candidate that targets 
the ID-DBL2x region of var2csa. Indeed, the ID1-DBL2x region is highly diverse, variants 
cluster in multiple distinct clades, and some clades may be more pathogenic than others. Vaccine 
efforts will have to take this relevant genetic diversity into account in order to develop an 
efficacious vaccine. A polyvalent vaccine constituting variants from multiple pathogenic clades 
will be more effective than the current monovalent vaccine candidates. 
 Our study was unique in that we used an integrative approach to achieve our aims. We 
leveraged advanced molecular methods (next-generation sequencing), population genetics, and 
molecular epidemiology to examine antigenic diversity of var2csa, identify immunologically 
relevant selection pressures and signatures of genetic relatedness to inform vaccine development 
efforts. This approach also allowed us to identify potential pathogenic clades which must be 
included in an efficacious polyvalent vaccine. Furthermore, using this integrative approach on 
field isolates collected from clinically well-defined cohorts of malaria- infected pregnant women 
from multiple malaria-endemic countries with differing transmission intensities allowed us to 
better characterize the extent of ID1-DBL2x genetic diversity and associations with adverse 
outcomes that were not possible from in vitro studies using laboratory isolates.  
In order to better understand the relationship between var2csa clade and pathogenicity, 
several questions and issues need to be addressed. The dimorphic region in the DBL2x domain 
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that separated the variants into the two vaccine clades should be investigated closely to define 
specific residues that are associated with adverse birth outcomes, especially at the amino acid 
level. These residues can be used in future studies to assess pathogenicity of specific var2csa 
clades around the world. Additionally, including growth percentile derived from nomograms as 
an outcome will allow for estimating the direct effect of specific clades on fetal growth. 
Measurement of immunity to var2csa will also help clarify the associations between var2csa 
variants and adverse birth outcomes. Thoroughly investigating the relationship between 
gravidity, a measure of past exposure and genetic diversity of var2csa in different transmission 
settings will help elucidate the role of acquired immunity on preventing the adverse effects of 
malaria infections during pregnancy. 
FUTURE DIRECTIONS 
Efforts must be taken to characterize the diversity of the ID1-DBL2x region on field 
isolates from other countries in Africa and around the world. The genetic and amino acid 
residues identified in the dimorphic region can serve as markers to investigate the diversity and 
pathogenicity of var2csa clades around the world. We also need to characterize the other vaccine 
candidate that targets the DBL1x-DBL2x region in the same manner we characterized the ID1-
DBL2x region in this project. Extensive investigations into the N-terminal region (NTS-DBL2x) 
of var2csa should also be a priority in order to identify other target regions that can help improve 
upon current vaccine candidates.  
As clinical trials get underway for testing vaccines against PAM, characterizing genetic 
diversity and genetic surveillance of parasite populations will help monitor changes that affect 
vaccine efficacy and inform future vaccine improvement and development efforts. The 
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multidisciplinary approach we used here can also be used to inform the development of future 
malaria vaccine candidates targeting polymorphic antigens. 
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 APPENDIX A: POWER CALCULATION 
 
Aim1: Assuming mean expected heterozygosity of the ID1-DBL2x-ID2 region of 0.3 with a 
standard deviation of 0.15 [47], a sample size of 100 pregnant women will yield 81.4% power to 
detect a 10% change in mean expected heterozygosity between primi-, secundi- and multigravid  
women using a Boneforrni corrected alpha of 0.0167 for multiple comparisons. Additionally, as 
the diversity of the ID1-DBL2x-ID2 region has not been well characterized, figure 3 shows the 
change in power to detect a range of differences in mean expected heterozygosity in the study 
population.  
 
Power curves for Aim 1  
   
 
The power to detect change in mean expected heterozygosity among women who gave birth to 
normal birth weight infants and women who gave birth to low birth weight infants will be higher 
as the alpha will increase to 0.05. The power to detect a 10% change in mean expected 
heterozygosity in this comparison will be 91%.  
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Aim 2: Assuming a sample size of 100 pregnant women and a standard deviation of 10%, we 
will have 86.7% power to detect a 200 gram difference in birth weight using a Boneforrni 
corrected alpha of 0.005 for multiple comparisons. 
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 APPENDIX B: LIST OF BARCODED PRIMERS USED 
 
 
 
 
Forward Primer ID Barcode Forward Barcoded primer (5'→3') 
 
Reverse Primer ID Barcode Reverse Barcoded primer (5'→3') 
Id1-F-MID22 TACGAGTATG TACGAGTATGGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID22 CATACTCGTA CATACTCGTAGTCGTGTATGTTGTCCA 
Id1-F-MID23 TACTCTCGTG TACTCTCGTGGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID23 CACGAGAGTA CACGAGAGTAGTCGTGTATGTTGTCCA 
Id1-F-MID24 TAGAGACGAG TAGAGACGAGGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID24 CTCGTCTCTA CTCGTCTCTAGTCGTGTATGTTGTCCA 
Id1-F-MID25 TCGTCGCTCG TCGTCGCTCGGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID25 CGAGCGACGA CGAGCGACGAGTCGTGTATGTTGTCCA 
Id1-F-MID26 ACATACGCGT  ACATACGCGTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID26 ACGCGTATGT  ACGCGTATGTGTCGTGTATGTTGTCCA 
Id1-F-MID27 ACGCGAGTAT  ACGCGAGTATGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID27 ATACTCGCGT  ATACTCGCGTGTCGTGTATGTTGTCCA 
Id1-F-MID28 ACTACTATGT  ACTACTATGTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID28 ACATAGTAGT  ACATAGTAGTGTCGTGTATGTTGTCCA 
Id1-F-MID29 ACTGTACAGT  ACTGTACAGTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID29 ACTGTACAGT  ACTGTACAGTGTCGTGTATGTTGTCCA 
Id1-F-MID30 AGACTATACT  AGACTATACTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID30 AGTATAGTCT  AGTATAGTCTGTCGTGTATGTTGTCCA 
Id1-F-MID31 AGCGTCGTCT  AGCGTCGTCTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID31 AGACGACGCT  AGACGACGCTGTCGTGTATGTTGTCCA 
Id1-F-MID32 AGTACGCTAT  AGTACGCTATGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID32 ATAGCGTACT  ATAGCGTACTGTCGTGTATGTTGTCCA 
Id1-F-MID33 ATAGAGTACT  ATAGAGTACTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID33 AGTACTCTAT  AGTACTCTATGTCGTGTATGTTGTCCA 
Id1-F-MID34 CACGCTACGT  CACGCTACGTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID34 ACGTAGCGTG ACGTAGCGTGGTCGTGTATGTTGTCCA 
Id1-F-MID35 CAGTAGACGT  CAGTAGACGTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID35 ACGTCTACTG ACGTCTACTGGTCGTGTATGTTGTCCA 
Id1-F-MID36 CGACGTGACT  CGACGTGACTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID36 AGTCACGTCG AGTCACGTCGGTCGTGTATGTTGTCCA 
Id1-F-MID37 TACACACACT  TACACACACTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID37 AGTGTGTGTA AGTGTGTGTAGTCGTGTATGTTGTCCA 
Id1-F-MID38 TACACGTGAT  TACACGTGATGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID38 ATCACGTGTA ATCACGTGTAGTCGTGTATGTTGTCCA 
Id1-F-MID39 TACAGATCGT  TACAGATCGTGATCCTTATTCCGCAGAATA 
 
CIDR-R-MID39 ACGATCTGTA ACGATCTGTAGTCGTGTATGTTGTCCA 
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 APPENDIX C: DEVELOPMENT AND OPTIMIZATION OF ID1-DBL2X 
GENOTYPING APPROACH 
 
 VAR2CSA is coded by a var gene in the P. falciparum genome. Var genes are 
infamously known to be incredibly large and diverse. The 1.6 kb fragment of the ID1-DBL2x 
region of var2csa has not yet been well characterized and there is limited data on the genetic 
diversity of the region. Hence, we developed and optimized our own approach to genotype the 
entire ID1-DBL2x region using long-read next-generation sequencing technology.  
 We initially started with a 3 kb fragment spanning DBL1x, ID1, DBL2x, and ID2 
regions. We aligned publicly available full length and partial genetic sequences of var2csa to 
identify conserved areas along the DBL1x-ID2 region for primer design. We found no regions 
flanking the DBL1x-ID2 fragment that were 100% conserved. As a result, we designed 
degenerate primer pairs in the most conserved flanking regions to account for the diversity.  
 The initial PCR assay for the 3 kb fragment included hi-fidelity taq polymerase and one 
round of amplification with a long elongation step (~3 minutes per cycle). We amplified seven 
parasite genomic lines (3D7, FCR3, 7G8, DD2, K1, RO33, and V1/S) and sequenced the PCR 
products using a primer walking approach. We confirmed the sequences from primer walking 
were indeed DBL1x-ID2 by comparing our results to publicly available sequences on GenBank 
and PlasmoDB. We then proceeded to test clinical placental samples from the ISTp trial. 
However, we were unsuccessful at amplifying the 3 kb fragment from genomic DNA extracted 
from dried blood spots from the ISTp placental samples collected at delivery. Increasing volume 
of DNA template to 5 µl helped increase the PCR yield but the improvement was marginal.  
 We then modified the PCR assay to target a smaller 1.6 kb fragment spanning the ID1-
DBL2x region which was recently recognized as the minimal binding epitope and a potential 
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vaccine candidate. Reducing to the 1.6 kb fragment improved our PCR amplification; however, 
we still had difficulty in consistently amplifying the fragment from clinical isolates. We then 
developed a hemi-nested PCR approach and designed an outer reverse primer that was used in 
the first round PCR. Primary PCR product was used DNA template for second round PCR which 
included the primers amplifying the 1.6 kb ID1-DBL2x region. Employing a hemi-nested 
strategy did significantly improve our PCR yields from clinical isolates; however, the success of 
PCR amplification from a clinical isolate depended on the quality of the extracted DNA. 
Additionally, when we added barcodes to both primer sequences for the second round PCR, we 
had to re-optimize the annealing temperature of the PCR assay to ensure consistent successful 
amplification of the ID1-DBL2x fragment. 
 We then compared our PCR amplification success rates using genomic DNA extracted 
from whole blood to the genomic DNA from DBS as template DNA for our hemi-nested PCR. 
Genomic DNA from whole blood performed significantly better even at lower concentrations of 
parasite DNA in amplifying the 1.6 kb fragment. Genomic DNA from whole blood also gave 
higher concentration and cleaner PCR products.   
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